朝雲集團營收、毛利率、除稅前溢利連續5個業績期增長 寵物營收翻番

香港，2025年8月28日 - (亞太商訊 via SeaPRwire.com) – 朝雲集團（06601.HK）發佈2025年中期業績報告，多項指標創下亮眼表現：營收同比增長7.2%，除稅前溢利同比增長5.3%，毛利率同比提升2.9個百分點，寵物業務營收增長超100%，線上渠道營收增長27.4%，疊加穩定派息與強勁現金流，公司盈利能力和經營質量進一步增強。營收增長及毛利率提升，股東回報持續穩定這已是朝雲集團連續5個半年度業績期實現營收、除稅前溢利增長，背後核心邏輯在於堅持"高質量、可持續、穩利潤"的經營原則：一方面，經營管理效率提升措施見效；另一方面，品牌力提升、品類與渠道結構持續優化，疊加供應鏈效率改善，推動整體毛利率同比提升2.9個百分點。這種"營收增長+毛利率提升"的雙箭頭，正是企業經營效率的直觀體現。除了盈利能力持續增長，朝雲集團持續回饋股東，中期高比例派息40%，實現股東收益最大化。截至6月末，公司現金、現金等價物及各項銀行存款總額達26.5億元，現金流持續強勁，為高派息政策的穩定落地提供了堅實資金保障，而"高增長+高派息+強現金"的組合也成為了當前市場環境下，稀缺的"安全標的"。寵物業務營收增長超100%，"潛力板塊"變"增長引擎"如果說整體增長是"穩"，那寵物業務就是最耀眼的"爆點"。財報顯示，朝雲集團2025上半年寵物業務營收從4800萬元飆升至9600萬元，同比暴增101.4%。毛利率同比增長8.6個百分點至58.1%，實現了營收和毛利率高增長。寵物業務成為驅動公司增長的核心引擎之一。家居護理業務穩坐龍頭，連續11年市占第一作為集團壓艙石，家居護理業務持續增長，營收同比增長4.3%，毛利率同比提升2.7個百分點至49.1%。其中，殺蟲驅蚊品類連續11年保持行業市占第一，家居清潔市占第二，龍頭地位穩固，形成"基本盤業務持續增長，新業務沖高增長"的良性循環。收入結構持續優化，線上渠道營收增長27.4%朝雲集團在渠道建設方面同樣亮眼，2025年上半年，朝雲線上渠道營收同比增長27.4%，毛利率提升5.5個百分點至59.9%。公司在深耕淘系、京東、拼多多等平臺基礎上，實現抖音等內容電商渠道爆發：營收同比增長101%，打造出更多的億元渠道的同時，線下渠道推行多品類的分銷覆蓋，加強高毛利產品的分銷數量和分銷網點的質量，鞏固市場領導地位。這意味著公司不僅在"賣得多"，更在"賣得好"，渠道結構優化帶來的利潤彈性正在釋放。供應鏈方面，持續進行供應鏈改革，通過對自有工廠實施技術改造、增加自動化生產線提升生產效率，對外協工廠精益化管理，對研發配方的升級創新，從而整體提升供應鏈運營效率，優化供應成本，增強整體盈利能力。2025年下半年，朝雲集團將秉持高質量、可持續、穩利潤的經營指導方針，保持強勁的現金流、持續提升盈利能力、持續落實高派息政策。聚焦家居護理業務、寵物業務拓展。鞏固線下分銷渠道的領先地位，增強電商業務的盈利能力。加強技術研發實現創新，推出更多差異化好產品，為公司未來發展注入新動力，打開更大的長期成長空間。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2025-08-28

商湯2025年中期業績發佈 2025上半年營收超市場預期按年增長36% 虧損大幅收窄

香港，2025年8月28日 - (亞太商訊 via SeaPRwire.com) – 商湯集團股份有限公司（「商湯集團」或「公司」，股份代號：0020）今日公佈截至2025年6月30日止半年度（「2025年上半年」）的中期業績。2025年上半年，商湯集團業績超出市場預期，總收入按年增長36%，達人民幣24億元；其中，生成式AI收入連續第三年高速增長，增幅達73%；經調整虧損淨額按年和按月均大幅收窄，按年下降50%；貿易應收回款額32億元，以96%大幅提升，達歷史新高。截至2025年上半年，集團的總現金儲備132億元。2025年上半年，商湯持續深化「1+X」戰略並取得實質性進展，完成業務動能穩健和結構優化。「1+X」以生成式AI與視覺AI作為「1」的核心業務，亦是雙引擎，而「X」代表的X創新業務板塊以孵化創新生態為核心戰略，聚焦智能駕駛、智慧醫療、家用機械人、智慧零售等四個賽道。生成式AI佔集團收入進一步提升至77%，日日新大模型多模態能力躋身世界前沿，大模型應用圍繞「生産力工具」和「互動工具」 兩大場景，快速提升滲透率和客戶忠誠度。當中生産力工具以商湯「小浣熊」産品為代表，提供金融、教育、政務三大版本，用戶數突破300萬。在互動工具領域，「日日新 V6.5」實現了文本與音視頻融合，多模態實時互動時數年內增長510%。視覺AI重啓增長曲綫，以高質量客戶策略和領先市場佔有率，實現利潤空間與現金流雙向改善。截至2025年6月底，視覺AI板塊服務國內外客戶660餘家，複購比例57%，上半年海外商機儲備與新訂單按年顯著增長。組織上，圍繞「1」和「X」進行二次聯合創業，形成專業化與多元化兼備的領導架構，針對創新業務任命獨立的聯創團隊，實現「X創新業務」在戰略重組後釋放經營活力與資本市場吸引力。商湯科技董事長兼首席執行官徐立博士表示：「在國務院發佈《關於深入實施「人工智能+」行動的意見》重要舉措的背景下，商湯緊抓落地機遇，深耕行業領域，以生成式AI與視覺AI為雙引擎，使商湯在繼續保持視覺AI龍頭地位基礎上，抓住生成式AI 所帶來的歷史性窗口，為員工、客戶和股東持續創造價值。」2025年上半年集團核心經營亮點- 整體收入按年增長36%，達到24億元人民幣，增速較往年進一步提升；經調整EBITDA與經調整淨虧損顯著改善，按年收窄幅度分別達72.5%和50%；- 應收款回款金額創歷史新高，達32億元人民幣，按年增長96%；貿易應收周轉天數同比縮短49%；- 經營活動現金流淨流出按年大幅收窄82%，現金創造能力不斷增强；總現金儲備攀升至132億元人民幣，為集團聚焦長期戰略實施提供了充裕的資金保障。關於商湯作為人工智能軟件公司，商湯科技以「堅持原創，讓AI引領人類進步」為使命，旨在持續引領人工智能前沿研究，持續打造更具拓展性更普惠的人工智能軟件平台，推動經濟、社會和人類的發展，並持續吸引及培養頂尖人才，共同塑造未來。商湯科技擁有深厚的學術積累，並長期投入於原創技術研究，不斷增强行業領先的多模態、多任務通用人工智能能力，涵蓋感知智能、决策智能、智能內容生成、自然語言處理等關鍵技術領域，同時包含AI芯片、AI傳感器及AI算力基礎設施在內的關鍵能力。此外，商湯前瞻性打造新型人工智能基礎設施——商湯AI大裝置SenseCore，打通算力、算法和平台，並在此基礎上建立「商湯日日新SenseNova」大模型及研發體系，以低成本解鎖通用人工智能任務的能力，推動高效率、低成本、規模化的AI創新和落地，進而打通商業價值閉環，解决長尾應用問題，引領人工智能進入工業化發展階段。商湯科技業務涵蓋生成式AI、視覺AI和X創新業務，相關産品與解决方案深受客戶與合作夥伴好評。商湯倡導「發展」的人工智能倫理觀，並積極參與有關數據安全、隱私保護、人工智能倫理道德和可持續人工智能的行業、國家及國際標準的制訂，與多個國內及多邊機構就人工智能的可持續及倫理發展開展了密切合作。商湯《AI可持續發展道德準則》被聯合國人工智能戰略資源指南選錄，並於2021年6月發表，是亞洲唯一獲此殊榮的人工智能公司。目前，商湯科技已於香港交易所主板掛牌上市。商湯在香港、上海、北京、深圳、成都、杭州、西安、新加坡、曼谷、吉隆坡、利雅得、阿布扎比、杜拜、首爾等地設立辦公室。另外，商湯科技在德國、泰國、印尼、菲律賓等國家均有業務。更多資訊，請瀏覽商湯科技網站、微信、微博和領英。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2025-08-28

China Everbright Limited Announces 2025 Interim Results

HONG KONG, Aug 28, 2025 - (ACN Newswire via SeaPRwire.com) - China Everbright Limited ("CEL" or "the Company", stock code: 165.HK) announced its Interim results for the six months ended 30 June 2025 ("the reporting period").Highlights of the 2025 Interim Results- Strong Growth: Total income reached HK$2,068 million, representing a significant increase compared with  the same period last year;- Turning Around from Loss to Profit: During the reporting period, the Company recorded a profit of HK$650 million, of which the net profit attributable to shareholders of the Company was HK$399 million, successfully turning around from a net loss;- Fundraising Increase: The total assets under management (AUM) of CEL's funds amounted to approximately HK$119.4 billion, with new fundraising amounting to approximately HK$2,741 million;- Successful Exits: The total exits from funds and principal investments amounted to HK$2.018 billionï¼›with a MOIC (multiple on invested capital) of approximately 2.78 times;- Cost Control and Efficiency Enhancement: Enhanced lean management led to a 10% year-on-year decrease in operating costs and a 38% year-on-year reduction in finance costs;- Adequate Liquidity:  The Company had cash and cash equivalents of approximately HK$8.1 billion;- Steady Dividend:  An interim dividend of HK$0.05 per share for 2025.In the first half of 2025, China's private equity industry entered a more stable stage of development. Leveraging its strengths as patient capital, CEL maintained strategic focus, seized market opportunities with precision, and promptly adjusted its fundraising, investment, management, and exit strategies. By consolidating its core businesses, gradually unlocking value potential, and significantly improving overall operational efficiency, the Company achieved a strong rebound in performance.During the reporting period, CEL realised total income of HK$2,068 million, representing a significant increase of HK$2,182 million from the same period last year. This was mainly due to a significant increase in investment income, which fully demonstrated the Company's sound investment vision and solid foundation in long-term investing. The Company recorded a profit of HK$650 million, of which the net profit attributable to shareholders of the Company amounted to HK$399 million, successfully turning around from a net loss attributable to shareholders of HK$1,282 million in the same period last year, representing a significant improvement in performance.Meanwhile, the Company continued to strengthen its refined management, sustaining healthy and steady business development. During the reporting period, operating costs represented a year-on-year decrease of 10%, with proactive leverage reduction measures implemented. The gearing ratio decreased by 2% compared with the end of 2024, while finance costs fell 38% year-on-year, demonstrating significant results in cost control and efficiency improvement. As at the end of June 2025, the Company had cash and cash equivalents of approximately HK$8.1 billion, representing sufficient liquidity.By concentrating its resources and business focus on high-potential products, the Company further reinforced its core business. During the reporting period, with new fundraising amounting to approximately HK$2,741 million, the total AUM of CEL’s funds amounted to approximately HK$119.4 billion, managing 72 fund products and covering primary market funds, secondary market funds, and fund of funds. During the reporting period, the Company invested in a total of 9 projects and exited, fully or partially, from 46 project.Following the practice of sharing the Company's operating results with shareholders, the Board declared interim dividend of HK$0.05 per share for 2025 (2024 interim dividend: HK$0.05 per share).Business Highlights in the First Half of 2025Firstly, CEL Harnessed the Strengths of Group-Based Operations to Enhance Fundraising SynergyIn the first half of 2025, the Company successfully launched the Huaian Hongze Guangqi Fund and the Xiamen Marine High-Tech Industrial Development Fund, with a total scale of RMB2.5 billion. The Huaian Fund targets growth-stage projects in the areas of new energy, new materials, and intelligent manufacturing, with its first round of capital contribution completed in the first half of the year. The Xiamen Marine Fund is dedicated to incubating and transforming scientific and technological innovations in the marine sector, driving the high-quality development of the marine economy. At the same time, several other funds have been approved and are progressing smoothly, following the established plan.Secondly, CEL Strengthened Core Businesses to Drive Robust Recovery in PerformanceDuring the reporting period, the Company total exits from funds and principal investments amounted to HK$2.018 billion. This include the full exit from Xpeng Motors, DAPU Telecom, and Taboola, alongside partial exit from iSoftStone, Dekon Food and Agriculture, 4Paradigm, and other projects. With a MOIC (multiple on invested capital) of approximately 2.78 times, these exits significantly boosted the DPI of multiple funds, generating substantial returns for LPs. Several listed projects, including Circle, Dekon Food and Agriculture, and NetEase Cloud Music, delivered strong market performance in the first half of the year, making notable contribution to the Company's investment returns. In the first half of the year, secondary market funds expertly capitalised on structural opportunities, achieving impressive investment performance. Notably, the Everbright Convertible Bond Opportunity Fund ranked second among similar funds in Barclays' performance rankings.Thirdly, CEL Anchored Strategy Around Scientific and Technological Innovation, With a Particular Focus on Key Industry SectorsGuided by deep industrial insight and a forward-looking strategic vision, the Company accelerated its investment activity in the first half of the year. It targeted emerging strategic industries such as artificial intelligence, chips and semiconductors, and biomedicine, with a total investment of approximately HK$264 million by funds. We have nurtured and supported a number of technology leaders, including Yangtze Memory and Wuhan Xinxin (both prominent domestic memory chip producers), HengYi Biotech (a company engaged in the research and development of innovative drug for tumors and autoimmune diseases), J-Sensor (astrategic supplier of domestic industrial automation modules and core sensors for new energy vehicles), and Tec-Do (a service provider in the field of big data and BI), among others. These investments reflect our commitment to strengthening China’s science and technology enterprises. Meanwhile, CEL supported excellent sub-funds such as Jinyi Capital and Eastern Bell Capital through its FoF platforms. These FoF investments allow us to fully leverage the advantages of resource amplification, risk diversification, and diversified returns.Fourthly, CEL Optimise Business Management to Unlock Growth MomentumIn the first half of the year, the Company continued to optimise its financing structure and took full advantage of the domestic interest rate cut cycle, issuing RMB3 billion in the first tranche of its 2025 medium-term notes at a coupon rate of 2.09% per annum — the lowest coupon rate in the Company's bond issuance history. During the reporting period, the Company's overall financing cost declined by 133 basis points year-on-year to 3.14%, while its finance costs reduced by 38% year-on-year. Operating costs also recorded year-on-year decrease of 10%, underscoring the solid progress made in reducing costs and increasing efficiency. The Company continued to optimise its risk management framework. CEL advanced the classification of risk assets, reinforced dynamic valuation management, and established a risk monitoring and early warning system, thereby improving the effectiveness of risk prevention and control across the full business cycle.Fifthly, CLE Enhanced Public Services and Upgraded Commercial Consumption.CEL leveraged its industrial strengths to enhance the quality of its products and services, catering to the growing demand for consumer services among citizens. In the commercial consumption arena, EBA successfully launched 18 "IMIX Park" shopping centres across nine cities nationwide,managing approximately 2.6 million square metres in total. These centres created approximately 37,700 jobs, attracted approximately 121 million customer visits, and hosted more than 4,500 tenant merchants in the first half of 2025. During the reporting period, Phase I of the "Zhongguancun ART PARK IMIX Parks", a flagship consumption infrastructure and urban renewal project in Beijing, opened smoothly, significantly upgrading the consumer experience and giving a strong boost to domestic demand.Sixthly, Key Portfolio Companies Maintain Stable Growth with Strong ResilienceThe core business of China Aircraft Leasing Group Holdings Limited (CALC) progressed steadily with remarkable improvements in operating quality and efficiency. The net profit attributable to shareholders recorded a year-on-year increase. As of June 30, 2025, CALC’s fleet reached 181 aircraft, leased to 41 airlines across 22 countries and regions. Everbright Senior Healthcare has been seizing the development opportunities in China's healthcare industry. As of 30 June 2025, Everbright Senior Healthcare has 237 institutions of various types in 49 cities across the country, it managed more than 30,000 beds, with occupancy rates increasing by 1.77%. Meanwhile, Terminus continued to deepen the integration of AI technology across multiple industries, driving intelligent transformation and implementing localised AI applications and digital-intelligent solutions, while receiving multiple authoritative certifications.Seventhly, CEL Strengthened ESG Framework to Promote Sustainable DevelopmentDuring the reporting period, CEL continued to promote the construction of its ESG system. the Company maintained an "A" rating in the MSCI ESG Rating and received the "BEST ESG (S)" award from the Hong Kong Investor Relations Association (HKIRA). The Company earnestly fulfilled its role as a corporate citizen by leveraging its own capabilities, organizing and participating in 46 cultural and social welfare activities in the first half of the year, serving over ten thousand people, and upholding high standards in discharging its social responsibilities.In the first half of 2025, under the strong leadership of the Everbright Group, the guidance of the Board of Directors, and the collective efforts of all employees, the Company achieved significant improvements in operational efficiency and quality, with new drivers of growth continuing to strengthen, resulting in hard-won achievements. As China's economy continues to improve and policy support intensifies, the Chinese private equity industry will embark on a new journey of high-quality development. CEL will seize market opportunities, capitalise on the momentum, and lay a solid foundation for a strong start to the 15th Five-Year Plan. In the second half of the year, CEL will continue to adhere to the overall principle of seeking progress while maintaining stability, continue to focus on revenue growth and cost control, optimise operational management, seize opportunities in key business areas such as fundraising, investment, management, and exit, leverage the cross-border platform and the synergistic advantages of the group, cultivate long-term patient capital, and advance the "five major financial initiatives", through scientific strategic planning, professional investment teams, and rigorous risk management,  and continuously create value for shareholders.China Everbright Limited, https://www.everbright.com/en [SHSE:601818][HKEX:00165][OTCPK:CEVIF][OTCPK:CEVIY] Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2025-08-28

Hong Kong Watch & Clock Fair, Salon de TIME return in September

HONG KONG, Aug 28, 2025 - (ACN Newswire via SeaPRwire.com) - The 44th HKTDC Hong Kong Watch & Clock Fair and the 13th Salon de TIME, jointly organised by the Hong Kong Trade Development Council (HKTDC), the Federation of Hong Kong Watch Trades & Industries Limited, and Hong Kong Watch Manufacturers Association Limited, themed “Our Time Our Moments”, are expected to attract over 650 exhibitors from 15 countries and regions, providing a one-stop sourcing platform for global buyers.Under the EXHIBITION+ hybrid model, the physical exhibitions will be held from 2 to 6 September at the Hong Kong Convention and Exhibition Centre. Salon de TIME is fully open for industry professionals and the public to visit and make purchases. Exhibitors and buyers can meet online through the Click2Match smart business matching platform between 26 August to 13 September.Number of participating brands hits post-pandemic highSophia Chong, HKTDC Deputy Executive Director, said: "As a globally renowned watch event, the Hong Kong Watch & Clock Fair and Salon de TIME continue to attract pavilions from France and Switzerland, as well as from Guangzhou and Taiwan. Additionally, exhibitors from Germany, Japan, Lebanon, and the Netherlands return with a range of uniquely designed watch products. The Salon de TIME features over 140 global brands, marking a new post-pandemic high. Aside from an increase in Hong Kong brands, there is also a rise in participating brands from Switzerland, France, and Germany, the three major watch-exporting countries in Europe. This high level of international representation underscores Hong Kong's advantage as an international business platform."According to the latest data, Hong Kong is the world's second-largest hub for watch imports and exports. In the first seven months of this year, the total export value was approximately HK$28.2 billion, with the decline narrowed from 8.2% during the same period last year to 2.7%, representing an improvement of 5.5 percentage points. Some individual markets recorded double-digit increases, including Brazil (+65%), France (+57%), Germany (+15%), and India (+35%). Additionally, the HKTDC Export Confidence Index for Timepieces rose from 51.2 to 52.1 in the second quarter, indicating the industry remains optimistic about the export outlook despite challenges.Distinctive niche brands and “Guochao” elegance at Salon de TIMESalon de TIME, located in the Hall 3FG, features six thematic zones, including the new zone Microbrands.  There are 12 unique niche brands offering watches that are both affordable and stylish. Other zones include World Brand Piazza, Renaissance Moment, Wearable Tech, Craft Treasure, and Chic & Trendy. Some of these brands provide on-site retail options, allowing the public to purchase their favourites. Also, this year the fair will welcome 18 brands from Mainland China and several independent watchmakers to present their “Guochao” series watches.World-renowned brands showcased at World Brand PiazzaSponsored by Prince Jewellery & Watch for the 15th consecutive year, World Brand Piazza remains a highlight of the exhibition. This year, the zone will feature 9 renowned international brands, including Baume & Mercier, Corum, CVSTOS, DeWitt, Kerbedanz, Montblanc, Peonia Diamond, Sarcar and Ulysse Nardin.The themed area showcases limited-edition and prestigious timepieces from top brands. For example, Corum is presenting the Golden Bridge Round 43 “Blue Sapphire”. a stunning new addition encased in 43mm of 18K white gold. The bezel is adorned with 96 baguette-cut blue sapphires, creating a vivid, luminous frame. At its heart beats the CO 113 hand-wound caliber—Corum’s signature linear movement—with 18k gold bridges and a 40-hour power reserve, visible through the sapphire crystal case.The Ulysse Nardin Freak One OPS wristwatch is cased in black DLC titanium, complemented by the special sunray-patterned barrel cover and bezel made of Carbonium®ï¸'. Freak ONE OPS’s calibre UN-240 Manufacture flying carousel movement is clearly visible. Power reserve up to 90 hours.Innovative sustainable materials cater to a new generationThe younger generation of customers increasingly values environmental, social, and governance (ESG) based products, prompting some watch brands to switch to recycled or sustainable materials. To make it easier for buyers to purchase products that meet environmental standards, this year's exhibition continues to feature a Green Solutions Suppliers label to identify over 20 selected exhibitors showcasing sustainable watches, including:German brand Lilienthal Berlin which follows the launch of the world's first watch with a case made from recycled coffee grounds last year, with a watch that features a dial made from recycled tea leaves, giving it a subtle tea fragrance.Hong Kong brand Memorigin presents the Genesis Series (Ocean Blue) tourbillon watch, featuring a polished metal case paired with an eco-friendly strap jointly created with Austrian strap manufacturer Hirsch. The strap is made from ocean recycled yarn, making it both stylish and environmentally friendly.Hong Kong brand Sunrex has launched a solar-powered watch inspired by space exploration, equipped with the Epson VS76A solar quartz movement. Once charged, it can run continuously for five months.Growing health consciousness creates opportunities for the watch industryIn recent years, the public's increasing focus on health and engagement in digital fitness has created new opportunities for the watch industry, driving the widespread adoption of smartwatches and sustaining growth within the industry. Featured products at the shows include:German brand Oskron has launched the Watch2Care “Western-Chinese Prevention” smartwatch, equipped with exclusive “Five Organs Digital Pulse Diagnosis” technology. Powered by data from 300,000 traditional Chinese medicine cases and advanced AI analysis, it helps users stay on top of their well-being. On 3 September, the brand has invited Professor Zhang Qiming from the China Academy of Chinese Medical Sciences to the event to consult and share health information with attendees.Saga, in collaboration with HONOR Connect, has launched a smartwatch featuring the market's smallest 35mm delicate smartwatch movement, specifically designed for women. It is equipped with health monitoring, 109 sports modes, 10-day battery life, and IP68 dust and water resistance.The two fairs also feature a variety of styles, as well as collaborations, limited-edition, or debut watches, catering to market demands:Sea-Gull presents the “Three-Legged Golden Sunbird” Minute Repeater with Gold Engraved Automata, featuring a dial inspired by Chinese mythology and crafted by renowned Chinese master engraver Mei Hua. It is equipped with the Sea-Gull independently developed ST9100 minute repeater movement. When it chimes the wings of the three-legged golden bird unfold, showcasing the modern beauty of Eastern aesthetics.FIYTA has launched a watch themed “Chang'e Flying to the Moon”, featuring an engraving of the Moon's South Pole-Aitken Basin on the caseback. The watch has a gradient black dial adorned with an 18k gold relief of the Earth and the Moon, complemented by rocket-shaped hands.Zbioland's collaboration with Harry Potter brings the "Dynamic Snake" watch, which will be unveiled for the first time during the fair, with a limited release of 200 pieces. Local brand UNDONE has launched the “Legends of Rock” series, paying tribute to rock legends, featuring a vinyl record player design on the dial. The caseback of each watch is printed with a unique image from the Rolling Stones’ photo assets, granting the watch owner full ownership of that image asset, making it particularly valuable for collectors.European independent watchmakers showcase exceptional craftsmanshipIn recent years, personalised niche watch brands have been gaining popularity, winning the favour of the younger generation and collectors through limited production and customisation options. This year, the Swiss Independent Watchmakers Pavilion (SIWP) and Francéclat bring together 19 international watchmaking brands, showcasing uniquely designed and expertly crafted watches, including:Swiss brand Aerowatch is celebrating its 115th anniversary by launching a limited edition “Milan” pocket watch, with only 115 pieces available. This watch blends traditional and modern styles, reflecting the brand's enduring legacy with a contemporary twist.Legendary French watchmaker and modernist artist Alain Silberstein has designed a bold, colourful, and uniquely styled watch, featuring a playful twist with Yema's in-house micro-rotor automatic movement.Eight specialised zones offering a one-stop procurement platformAt the Hong Kong Watch & Clock Fair in the ground-floor exhibition hall, there are eight specialised zones.  Pageant of Eternity will showcase high-end complete watches produced through Original Equipment Manufacturing (OEM) and Original Design Manufacturing (ODM). Other zones include Complete Watches, Clocks, Machinery & Equipment, OEM Smart Watches, Packaging & Display, Parts, Components & Accessories, and Trade Services.Forums and seminars explore industry trendsDuring the fairs, more than 35 unique events will be held, including forums, seminars, watch parades, and networking activities, to help industry professionals stay informed about market trends.On the first day (2 September), the Hong Kong International Watch Forum will be held, featuring leaders from watch associations in mainland China, Germany, France, Switzerland, Japan, and Korea who will share the latest regional trade data and industry trends and discuss global supply chain strategies.On the second day (3 September), the Asian Watch Conference will focus on the theme “Redefining Eternity: Trends, Values, and Visions in Watchmaking”. A senior analyst from international market researcher Euromonitor International (Hong Kong) will share insights on the latest developments in the watch market. Additionally, an independent watchmaker and chief representative from the SIWP, along with a seasoned independent watch collector, member of the Academy of the Grand Prix d'Horlogerie de Genève (GPHG), will discuss the art and philosophy of independent watchmaking and microbrands.On the second day, there will be two additional events focused on the theme of Chinese trends. One is the Chinese Watchmaking 70th Anniversary: Panel Discussion and Watch Preview, organised by Fosun Watch Group, featuring Sea-Gull and Shanghai Watch. The other is “To the Stars and Beyond: The Chinese Independent Watchmaking”, which will explore the current state of development of Chinese independent watchmakers and the essentials of independent watchmaking.The HKTDC, the Federation of Hong Kong Watch Trades & Industries Limited, and the Hong Kong Watch Manufacturers Association Limited are also jointly organising the 42nd Hong Kong Watch & Clock Design Competition to promote watch design and nurture local creativity. This year, the open group and student group have themes of “Memorable” and “Believe in Yourself” respectively. The competition continues to include the Made-to-Sell Award to recognise student work with significant market potential.Celebrity Bowie Cheung who served as a guest judge will attend the award ceremony. The winning and shortlisted designs will be displayed during the fair, and the award ceremony will be held on 6 September at the event stage.A variety of events, lucky draws and workshop for the publicSalon de TIME will host a variety of special events and watch presentations. On the fourth day (5 September), Hong Kong metal engraving artist Carlos Koo will demonstrate the art of watch engraving.The Smart Bidding event will be held again, and attendees can enjoy exclusive starting prices to bid on their preferred watches, including brands such as Saga, Anne Klein, and Elmer Ingo. Additionally, there will be the Beijing Watch 66th Anniversary Special Edition, the Sea-Gull 1963 Times Edition and the Shanghai Watch Tribute to 1955 Series 70th Anniversary Moon Phase Limited Edition.A lucky draw will be held every day during the five-day exhibition, giving attendees the chance to win luxurious watches, including those from Claudia Koch, Alexus Christy, Shanghai Watch, Sea-Gull, and the Memorigin Genesis Series (Ocean Blue) tourbillon watch, paired with the latest eco-friendly watch straps.Other exciting events include watch showcases and launch events, with appearances by celebrities including Aka Chio, Michael Tong, Kaman Kong, and Olympic karate medallists Grace Lau and Ariel Torres.Additionally, CENTRESTAGE will be held from 3 to 6 September at the HKCEC bringing together fashion brands and designer collections from around the world. Attendees will have the opportunity to explore the latest products from approximately 400 watch and fashion brands.The export performance of watches & clocks industry in Hong Kong: Jan-Jul, 2025Jan-Jul, 2024Total export value-2.7% (YoY)-8.2% (YoY) Photo download: http://bit.ly/45WjTz9The 44th HKTDC Hong Kong Watch & Clock Fair and 13th Salon de TIME take place on 2 to 6 September at the Hong Kong Convention and Exhibition Centre. Introducing fair highlights at a press conference are Sophia Chong, HKTDC Deputy Executive Director (center), Ethan Cheung (right) and Vincent Chan (left), Co-Chairmen, HKTDC Hong Kong Watch & Clock Fair Organising Committee 2025 The watch parade featured some 30 selected luxury watchesGerman brand Lilienthal Berlin is debuting a watch that features a dial made from recycled tea leaves   German brand Oskron has launched the Watch2Care “Western-Chinese Prevention” smartwatch, equipped with exclusive “Five Organs Digital Pulse Diagnosis” technology. Powered by data from 300,000 traditional Chinese medicine cases and advanced AI analysis, to help users stay on top of their well-being For the 15th consecutive year, the World Brand Piazza, in collaboration with Prince Jewellery & Watch, continues to be the highlight of the exhibition. This year, Prince Jewellery & Watch is presenting luxurious pieces from 9 internationally renowned watch brands, including the new limited edition Golden Bridge Round 43 "Sapphire" wristwatch by Corum (left), and the Ulysse Nardin Freak One OPS wristwatch (right)Sea-Gull presents the “Three-Legged Golden Sunbird” Minute Repeater with Gold Engraved Automata, featuring a dial inspired by Chinese mythology and crafted by renowned Chinese master engraver Mei HuaZbioland's collaboration with Harry Potter brings the "Dynamic Snake" watch, which will be unveiled for the first time during the fair, with a limited release of 200 pieces Local brand UNDONE has launched the “Legends of Rock” watch series, paying tribute to rock legends, featuring a vinyl record player design on the dialFrench legendary watchmaker and modernist artist Alain Silberstein has designed a bold, colourful, and uniquely styled watch, featuring a playful twist with Yema's in-house micro-rotor automatic movement  The 42nd HK Watch & Clock Design Competition has two categories – “Memorable” for the Open Group and “Believe in Yourself” for the Student Group. Award-winning work and finalists will be exhibited during the fairsWebsites:Hong Kong Watch & Clock Fair: https://www.hktdc.com/event/hkwatchfair/enSalon de TIME: https://www.hktdc.com/event/te/enMedia enquiriesPlease contact the HKTDC Communications & Public Affairs Department: Johnny Tsui,  Tel: +852 2584 4395,  Email: johnny.cy.tsui@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. https://www.hktdc.com Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2025-08-28

王朝酒業2025年上半年葡萄酒銷售收入達1.23億港元 產品組合優化 毛利率上升至39%

財務摘要 (未經審核)（港幣千元）截至六月三十日止六個月2025年2024年收入122,775135,347毛利47,27748,767本公司所有者應佔溢利8,17218,510毛利率39%36%每股基本盈利 (港仙)0.581.31香港，2025年8月28日 - (亞太商訊 via SeaPRwire.com) – 中國優質葡萄酒生產商王朝酒業集團有限公司（「王朝」或「集團」）（股份代號：00828）今日公佈截至2025年6月30日止未經審核之中期業績。2025年上半年，由於集團加強沿海地區乾白酒市場的開拓力度，推出新的白葡萄酒及起泡葡萄酒產品，集團白葡萄酒產品的銷售收入保持良好勢態。但受中國宏觀經濟及消費市場波動的影響，集團產品（尤其是高端葡萄酒產品）銷量下跌，以及由於推廣及宣傳開支增加，集團2025年上半年收入較2024年同期下跌9%至約1.23億港元，本公司所有者應佔溢利較2024年同期減少56%至約8.2百萬港元，每股基本盈利約為每股0.58 港仙。期內由於產品組合優化，集團毛利率由去年同期的36%上升至39%。集團白葡萄酒產品的銷售於期內為集團的主要收益貢獻來源。紅葡萄酒與白葡萄酒產品的銷售收入分別佔集團整體收入約41%及54%。期內，紅葡萄酒產品和白葡萄酒產品的毛利率分別為38%及39%。本集團積極求新，聚焦「5+4+N產品戰略」，其中「N」代表集團推出N項需求定制，不斷開拓創新產品，以滿足中國不同類型消費群體的多元化需求。於回顧期內，本集團繼續推出新產品及進行產品升級，以更好地滿足不同葡萄酒口味及不同消費能力的消費者，旨在激發品牌活力，並鞏固王朝作為國產葡萄酒代表的品牌形象。本集團以「王朝」品牌產銷超過100種葡萄酒產品，迎合中國葡萄酒市場大眾市場分部不同消費者群的各項需求和喜好。於回顧期內，本集團推出中高端新品－王朝乙巳蛇年生肖紀念乾紅葡萄酒，與中國生肖文化相融合，引領「國潮風」，以年輕化的視覺語言呈現生肖文化，吸引潛在消費者。於本期間，本集團持續加強與酒業協會的合作，開展「龍行高校」等活動，進一步擴大品牌在年輕族群中的認知度與美譽度。基於其現有的優質產品，本集團繼續推出新產品並推進產品升級。本集團於二零二五年三月在第112屆全國糖酒商品交易會上推出天陽茶酒系列、王朝百馥VSOP白蘭地等新品，以進一步完善其產品矩陣，為消費者提供多元的消費選擇。該系列茶香葡萄酒突破傳統葡萄酒的局限，以「茶酒融合」為核心理念，憑藉獨特的釀造工藝迅速獲得市場目光。這款茶香葡萄酒以白酒為基調，融合茉莉花及普洱茶的芬芳，在傳統的氣泡酒領域中，創造出一種全新的東方韻味。在全國糖酒商品交易會期間，本集團亦舉辦品酒會，王朝天夏酒莊的新品憑藉獨特的風味和精湛的釀造工藝，贏得業界的好評。除致力於中國核心葡萄酒業務外，本集團亦將通過新設立的合資公司，拓展新的酒類飲料領域，如醬香型白酒、黃酒及特種黃酒－陳皮酒，以實現收入來源的多元化。王朝醬香型白酒產品，即「漢」、「唐」、「宋」、「明」，已於天津核心市場新推出並得到熱烈迴響，並將於下半年進一步戰略推廣至其他地區。醬香型白酒產品滿足不同消費習慣的客戶群體的需求，並為本集團業務作出貢獻。未來，醬香型白酒產業的發展及擴張及客戶群體水平的持久提升，必將有效推動王朝葡萄酒及相關產品銷售的增長，從而提升我們的行業影響力及品牌知名度。對於黃酒項目，經規劃後，正於二零二五年下半年在江蘇建設一座儲罐容量為3,000噸黃酒及特種黃酒－陳皮酒的生產廠房。於建設工程竣工後，本集團將能夠生產特種黃酒－東台陳皮酒，讓本集團可有效擴展產品品類，把握中國黃酒行業的發展機遇，實現酒業高質量發展的重大戰略舉措。電商銷售方面，於回顧期內，本集團的電商團隊於傳統電商平台全面運營在線商店銷售產品，例如京東商城、天貓商城及拼多多，以及通過興趣電商平台（包括小紅書app、快手app及抖音app）全面創新品牌、品類、業務體系、流程和模式。本集團的自主品牌傳播使其可繼續獲得主流消費群體和圈子的關注，並提高本集團面向年輕消費者的產品的有效市場滲透率。同時，電商團隊積極培養電商直播人才，以進一步擴大其銷售渠道及建立新客戶群。此外，於回顧期內，本集團在大型葡萄酒品鑒大賽中屢獲殊榮。在多個獎項中，「王朝錦邑桶藏12年XO白蘭地」榮獲二零二五年國際葡萄酒與烈酒大賽（「IWSC」）中的銀獎。該比賽被視為葡萄酒和烈酒質量的國際評價標準。王朝百馥VSOP白蘭地、金王朝馬瑟蘭乾紅葡萄酒以及天陽茶酒系列亦於中國酒業協會舉辦的「二零二四年青酌獎」各類別評選中獲獎。「王朝夢園白葡萄酒」亦以其卓越的酒質榮獲二零二五年春季FIWA法國國際葡萄酒大獎賽中國區金獎。此外，「王朝傳承系列－乾紅葡萄酒」於同一比賽中榮獲金獎。該等葡萄酒因其酒香優雅、酒體順滑和口感圓潤從眾多參賽作品中脫穎而出，並在比賽中獲得獎項，向國家及世界展示了王朝葡萄酒的魅力和實力。王朝主席萬守朋先生總結︰「展望二零二五年下半年，本集團將繼續聚焦市場和消費者需求，並通過技術創新提升產品質量。同時，本集團將繼續創新營銷策略，激發品牌活力，進一步擴大王朝產品的市場份額，加強王朝品牌作為國產葡萄酒代表的形象，並為中國葡萄酒行業樹立標桿，將王朝美酒風尚帶給更多的中國消費者。本集團將繼續通過產品品類及消費場景的創新，以及跨行業合作，積極開拓新的營銷前景，以提升銷量，藉此支持國家擴大內需及釋放消費增長潛力的工作。」關於王朝酒業集團有限公司王朝酒業集團有限公司於2005年1月26日在香港聯合交易所有限公司主板上市，股份代號00828。成立於1980年，王朝爲中國優質葡萄酒生産商，主要生産及銷售「王朝」商標的葡萄酒産品，是中國第一家中外合資的釀酒企業，主要股東包括天津食品集團有限公司及法國葡萄酒巨頭人頭馬集團。集團產銷葡萄酒產品系列超過100種，及引入進口葡萄酒產品，為國內各消費層提供高質素及物超所值的葡萄酒。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2025-08-28

Dynasty’s Sales Revenue of Wine Products for the First Half of 2025 Reaches HK$123 Million

Financial Highlights (Unaudited)(HKD Thousand)Six months ended 30 June20252024Revenue122,775135,347Gross Profit47,27748,767Profit Attributable to Owners of the Company8,17218,510Gross Profit Margin39%36%Basic Earnings per Share (HK cents)0.581.31HONG KONG, Aug 28, 2025 - (ACN Newswire via SeaPRwire.com)  Dynasty Fine Wines Group Limited (“Dynasty” or the “Group”) (Stock Code: 00828), a premier grape winemaker in China, today announced its unaudited interim results for the six months ended 30 June 2025.In the first half of 2025, as the Group strengthened the effort for dry white market in coastal region and the new launch of white wine and sparkling wine products, the Group’s sales revenue of white wine products maintained a good momentum. But due to the impact of macroeconomy, fluctuations in consumer market in the PRC, as well as increase in marketing and promotion expenses, the Group's revenue for the first half of 2025 decreased by 9% to approximately HKD 123 million compared to the same period in 2024. Profit attributable to owners of the Company declined by 56% to approximately HKD 8.2 million year-on-year. Basic earnings per share were approximately HK0.58 cents per share. The overall gross profit margin increased to 39% from 36% for the corresponding period in 2024, mainly due to optimisation of product mix during the period.Sales of white wines products of the Group served as the Group’s primary revenue contributor during the period. Sales revenue of red and white wines products accounted for approximately 41% and 54% of the Group’s overall revenue respectively for the period. During the period, the gross profit margin of red wine products and white wine products were 38% and 39% respectively.The Group has been actively pursuing innovation, embracing the “5+4+N” product strategy, with “N” standing for developing various customised products and continuously creating new products to meet the diverse needs of different Chinese consumer groups. During the period under review, the Group continued launching new products and carrying out product upgrade, that can better suit different palates, and cater for consumers with different spending power. That was done with an aim to invigorate the brand, as well as consolidating the image of Dynasty representative of domestic grape wine brand. The Group produced a wide range of more than 100 wine products under the “Dynasty” brand to meet the demands and preferences of different consumer groups mainly in the mass-market segments in the PRC wine market. During the period under review, the Group launched a new high-end product, i.e. Dynasty Chinese Zodiac Commemorative Dry Red Wine for the Yi Si Year of Snake, integrating with the Chinese zodiac culture and the leading rise of Chinese style fashionable products, by presenting the zodiac culture in a youthful visual language to attract potential consumers. During this period, the Group continued strengthening cooperation with the Wine Association and carried out activities such as "Dragon University Tours" to further expand the brand's awareness and reputation among young people. Based on its existing high-quality products, the Group continues to introduce new products and promote product upgrades. The Group participated in the 112th China Food & Drinks Fair in March 2025, introducing new products such as Tianyang Tea-flavoured wine series, Dynasty Baifu VSOP brandy, etc., to further improve its product matrix and provide consumers with diverse consumption choices. Breaking through from the constraints of traditional wine, this tea-flavoured wine series, with its core concept of "tea and wine fusion", has captured market attention with its unique craftsmanship. Based on white wine, this Tea-flavoured wine infuses the aromas of jasmine and Pu'er tea, creating a new oriental flavour within the traditional sparkling wine landscape. During the China Food & Drinks Fair, the Group also held wine-tasting events, where the new wines from Dynasty Tianxia Winery won industry praise for their unique flavor and exquisite craftsmanship.Further to our commitment to core wine business in the PRC, the Group will develop new alcoholic beverages segments such as sauce-flavour baijiu, yellow wine and special yellow wine – Chenpi wine, through the newly set up joint venture companies, so as to diversify the sources of revenue. Dynasty sauce-flavour baijiu products, namely ‘Han’, ‘Tang’, ‘Song’ and ‘Ming’ have been newly launched in Tianjin core-market with enthusiastic responses and will be further strategically promoted to other regions in the second half of the year. The sauce-flavour baijiu products satisfy the needs of customer groups with different spending habits and contributing to the Group’s business. In the future, the continuous development and expansion of the sauce-flavour baijiu industry and the improvement of the level of customer groups will inevitably and effectively drive the increase in the sales of Dynasty wine and related products, thereby enhancing our industry influence and brand awareness. For the yellow wine project, after planning, a manufacturing plant with a tank capacity of 3,000 tonnes of yellow wine and special yellow wine – Chenpi wine in Jiangsu will be under construction in the second half of 2025. Upon completion of the construction works, the Group will be able to produce special yellow wine – Dongtai Chenpi Wine which allows the Group to effectively expand product categories, seize development opportunities in the Chinese yellow wine industry, and achieve a major strategic move towards high-quality development of the wine industry.Regarding E-commerce sales, the e-commerce team of the Group comprehensively operated online stores on traditional e-commerce platforms, such as JD.com, Tmall and Pinduoduo for product sales, as well as comprehensive innovation on its brand, product categories, and business systems, procedures and models via interest-based ecommerce platforms, including RED, Kuai and TikTok during the period under review. The Group’s autonomous brand communications could continue to gain the attention of mainstream consumer groups and demographic segments, and enhance effective market penetration of the Group’s products targeted at young consumers. The e-commerce team also actively cultivate e-commerce live broadcasting talents to further expand its sales channels so as to build up a new customer base.In addition, during the period under review, the Group had boasted brilliant results in major wine appraisal competitions. Among the numerous awards, “Dynasty Jin. Y Brandy XO barrel-aged 12 years” has won the Silver Award, at the 2025 International Wine & Spirit Competition (“IWSC”). The competition is considered the international standard for wine and spirits quality. Dynasty Baifu VSOP Brandy, Golden Dynasty Marselan Dry Red Wine, as well as Tianyang Tea-flavoured Wine series are also awarded at the “2024 Qingzhuo Awards” in respective categories by China Alcoholic Beverages Association. “Dynasty Mengyuan White wine” has also won the Grand Gold Medal at the France International Wine Awards (“FIWA”) China region, Spring 2025 for its excellent quality. In addition, “Dynasty Inherit series -Dry Red Wine” has garnered the Gold Award at the same competition. These wines stood out from other entries for their elegant aroma, smooth body and round taste, and won the awards at the competitions, showing the charm and strengths of Dynasty wines to the country and the world.Mr. Wan Shoupeng, Chairman of Dynasty, concluded, “Looking ahead to the second half of 2025, the Group will continue to focus on market and consumer demand and promote product quality through technological innovation. At the same time, the Group will continue to innovate marketing strategies to stimulate brand vitality, further expand the market share of Dynasty’s products, strengthen Dynasty’s brand image representative of domestic wines, and set a benchmark for the Chinese wine industry, with the aim of bringing Dynasty’s superior wines to more consumers in the PRC. The Group will continue to proactively develop new marketing prospects through innovation in product categories and consumption scenarios, and cross-industry co-operations in order to boost sales volume, which is in line with the country’s effort to promote domestic consumption and release the consumption growth potential.”About Dynasty Fine Wines Group LimitedDynasty Fine Wines Group Limited was listed on the Main Board of The Stock Exchange of Hong Kong Limited with the stock code 00828 on 26 January 2005. Founded in 1980, Dynasty is the premier grape winemaker in China. It is principally engaged in the production and sale of grape wine products under its reputable “Dynasty” brand. Dynasty is the first Sino-foreign joint venture wine company in China with Tianjin Food Group Limited and the French grape wine giant, Remy Cointreau, as its current major shareholders. The Group produces and sells more than 100 grape wine product series, and introduces imported wine products, providing high-quality and value-for-money grape wines to the full range of consumer groups in China. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2025-08-28

澳優2025年上半年業績公告 營收利潤持續韌性雙增長 國際業務和營養品成為第二增長引擎

香港，2025年8月28日 - (亞太商訊 via SeaPRwire.com) - 8月27日，澳優乳業股份有限公司（股份代號：1717.HK，以下簡稱"澳優"或"公司"）發布2025年上半年業績公告。公告顯示：2025年1-6月，澳優實現營業收入約人民幣38.87億元，同比增長5.6%；實現EBITDA（息稅折舊及攤銷前利潤）約人民幣3.98億元，同比增長29.7%；歸屬于母公司權益持有人應占利潤約人民幣1.81億元，同比增長24.1%，實現營收利潤持續韌性雙增長。 公告表示，2025年上半年，面對複雜多變的全球經濟形勢及競爭加劇的中國嬰配粉市場環境，澳優穩步推進"奶粉+營養品"全家營養戰略，進一步打造産品力、品牌力、渠道力、數智力及組織力，在消費者的信任、社會各界的支持和全體澳優人的共同努力下，營收、利潤繼續保持雙增長趨勢，以堅韌不拔的毅力和穩健扎實的步伐邁向高質量發展新階段。分版塊看，澳優自有品牌奶粉業務實現整體營收約人民幣28.26億元。其中，羊奶粉業務實現收入18.65億元，同比增長3.1%，"領頭羊"地位持續穩固，尼爾森IQ數據顯示截至6月底公司羊奶粉市場占有率同比提升2.8個百分點至30.4%；在2024年中國進口嬰幼童羊奶粉市場銷售量份額及銷售額份額均高達84%，已連續7年在中國進口嬰幼童羊奶粉市場份額超6成。【1】與此同時,弗若斯特沙利文經市場研究確認：2024年佳貝艾特羊奶粉銷量與銷售額全球第一。【2】牛奶粉業務實現收入約人民幣9.61億元。營養品業務實現收入同比增長7.0%，幷成功拓展至海外市場。分區域看，2024年羊奶粉中國業務實現收入約人民幣13.81億元；羊奶粉國際業務實現收入約人民幣4.83億元，同比大幅增長65.7%，國際業務多點開花，實現爆發式增長，在公司自有品牌配方羊奶粉業務總收入的占比進一步提升至25.9%。公告顯示，中東地區在2025上半年繼續保持澳優海外最大銷售市場的地位；北美地區收入同比提升逾138.7%，成為澳優海外市場第二大營收來源，獨聯體地區收入同比增長33.8%。澳優在公告中表示，羊奶粉業務海外市場在過去兩年保持高雙位數複合增長率的基礎上，于上半年再攀高峰，實現同比增長65.7%；營養品業務戰略布局全面起勢，成為驅動公司發展的重要動力。數據來源：【1】尼爾森IQ進口嬰幼童羊奶粉零售追踪數據；時間段：2018年-2024年，連續7個年度；渠道範圍：上海、江蘇、浙江、安徽、河南、廣東、湖南、湖北、福建、江西、北京、天津、黑龍江、吉林、遼寧、山東、山西、河北、陝西、四川、重慶、貴州、雲南、廣西的城市母嬰渠道。【2】弗若斯特沙利文Frost & Sullivan《全球羊奶粉市場獨立研究報告》（2025年4月）。基于對全球羊奶粉市場的研究，對2024年全球範圍內主要羊奶粉品牌的銷量以及銷售額進行研究分析後做出的確認，調研數據覆蓋2024年1月至12月。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2025-08-28

Genetec reinforces foundation for growth, maintains resilient outlook

Healthy pipeline, diversification and cost discipline position the Company for long-term growthKey Financial Performance Highlights for the Financial Year (FY2025):- Group’s total revenue for the financial year is RM222.7 million, mainly driven by the e-mobility and energy storage segment, supplemented by the electronics segment.- Recorded LAT of RM40.9 million for Q4FY2025 and LAT of RM27.2 million for the financial year.BANGI, Malaysia, Aug 28, 2025 - (ACN Newswire via SeaPRwire.com) - Technology leader in providing turnkey, intelligent manufacturing automation solutions, Genetec Technology Berhad (“Genetec” or the “Company”), today announced its financial results for the year ended 30 June 2025 (“FY2025”). The Company reported a gross profit of RM12.7 million for FY2025, supported by continued deliveries in the e-mobility and energy storage segments. The Company recorded a loss after tax (LAT), mainly reflecting higher logistics costs and non-operational, one-off expenses, while underlying fundamentals remain intact.Performance was affected by logistics constrains and one-off costs. Despite this, the Company continued to invest in strengthening its capabilities and supporting future project scopes. Profitability is expected to normalise in FY2026 as markets stabilise and as projects are executed effectively. Genetec is also reinforcing its organisation by bringing in experienced professionals into strategic roles, aimed at broadening capabilities and supporting its long-term diversification strategy.Healthy Orderbook through Diversified MarketsThe Company’s order and tender books remain intact and healthy, underpinned by recurring orders from existing clients as well as new opportunities from a more diversified client base across multiple industries and regions.Deepening Engagement with Existing ClientsAlongside diversification, Genetec continues to strengthen partnerships with its existing clients. Recurring orders and new programme awards reflect the trust and confidence these clients place in Genetec’s execution capabilities and proven track record.Global Manufacturing Trends Creating TailwindsGlobal geopolitical shifts are leading manufacturers across industries to re-evaluate their production footprints and enhance operational resilience. This trend is fuelling greater demand for automation solutions that are flexible, cost-competitive, and consistently high in quality. With its Malaysia-based production model, strong international track record, deep technical know-how, and agile manufacturing capabilities, Genetec is well-positioned to support clients as they navigate and adapt to these evolving requirements.Positive Outlook for BESS PipelinesThe Battery Energy Storage System (BESS) segment continues to gain momentum, with Genetec executing projects across domestic and international markets, and seeing growing local interest in BESS solutions for peak shaving following the recent tariff revision.Chief Executive Officer and Co-founder of Genetec, Chin Kem Weng commented, “FY2025 was a year of investment and transition. We made deliberate strategic choices to strengthen our foundation, safeguard delivery timelines, and support new project scopes. While these factors impacted margins in the short term, they reinforce our capabilities and credibility as a trusted partner. We expect profitability to normalise as market stabilise and as we build on execution experience.”“At the same time, our pipelines remain healthy, supported by recurring orders from existing clients and new opportunities across diversified industries and regions. Our inclusion in both the conventional and Shariah FTSE4Good Bursa Malaysia indices reflects the strength of our governance and sustainability practices. As Genetec approaches our 30th year in business, we remain committed to creating long-term value for clients, shareholders, and stakeholders.”About Genetec Technology BerhadGenetec Technology Berhad is a public listed company on the Main Market of Bursa Malaysia Securities Berhad (Stock code: 0104) and a global leader in providing customised, turnkey smart factory automation solutions. With a strong international footprint, it serves a diverse range of industries including electric vehicle (EV), e-mobility and energy storage, automotive, hard disk drives (HDD), consumer electronics, appliances, and pharmaceuticals.For more information please visit: https://genetec.net/.Issued on behalf of Genetec Technology Berhad by Narro CommunicationsFor media enquiries on Genetec Technology Berhad, please contact:Farah Shahrul                                               Narro Communications                               E: farah@narrocomms.com                           Joyce ShaminiNarro CommunicationsE: joyce@narrocomms.com Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2025-08-28

華領醫藥公佈2025年中期業績

- 华堂宁(R)銷量同比增長108%，淨銷售額同比增長112%。醫保覆蓋持續擴大，二級和三級醫院處方量顯著增加，全面自主商業化成效顯著。- 與拜耳終止獨家推廣服務協議後，確認一次性遞延收入人民幣12.435億元，實現上半年盈利11.839億元，公司在業績期內首次實現盈利。- 在中國開展涉及80個中心和2000名2型糖尿病患者的真實世界研究，進一步證明多格列艾汀的廣泛適用性和安全性。- 多格列艾汀75mg（商品名：MYHOMSIS(R)，華領片TM）在香港遞交註冊申請，加速佈局大中華區及東南亞市場。- 毛利率顯著提升，生產規模與運營效率持續優化。上海，2025年8月28日 - (亞太商訊 via SeaPRwire.com) - 華領醫藥（"公司"，香港聯交所股份代號：2552）宣佈公司及其附屬公司截至2025年6月30日止六個月（"報告期"）未經審核的綜合業績，以及公司上半年業務進展與未來展望。報告期內，公司核心產品华堂宁(R)（多格列艾汀片）商業化加速，自主運營能力顯著提升，研發進展順利推進，財務表現實現突破性成長，為長期可持續發展奠定了堅實基礎。華領醫藥創始人兼首席執行官陳力博士表示："2025 年上半年是華領醫藥轉型發展的關鍵階段。全面接管华堂宁(R)商業化後，公司憑藉自主搭建的銷售團隊，實現了銷量與收入的翻倍增長，印證了新的商業模式的有效性。我們還在中國香港遞交了新藥上市申請，為多格列艾汀從中國走向東南亞乃至全球市場奠定了基礎。同時，多格列艾汀在真實世界研究中持續展現出廣泛的治療潛力，也在基礎研究中發現了糖尿病緩解、認知改善、血脂改善和增肌等方面的新證據，進一步鞏固了華領醫藥在GKA研發和治療領域的全球領先地位。未來，華領醫藥將繼續深耕糖尿病和整個代謝疾病領域，通過創新研發與市場拓展的雙輪驅動，讓中國原創新藥惠及更多全球患者。"業務亮點與運營進展商業化轉型成效顯著，銷售與利潤雙增長- 2025年1月1日起，公司終止與拜耳的獨家推廣服務協議，全面接管华堂宁(R)在中國的商業化運營。報告期內，在與2024年同期的單價保持一致的情況下，华堂宁(R)銷量達176.4萬盒，同比增長108%；淨銷售額達2.174億元，同比增長112%。憑藉強勁的商業執行力和不斷提升的運營效率，公司邁向盈利。華領醫藥已順利過渡到全面自主商業化階段，也印證了日益增長的市場需求和自主銷售團隊的高效執行力。- 2024年被納入中國國家醫保藥品目錄(NRDL)後，2025年华堂宁(R)繼續受益於廣泛的醫保覆蓋，二級和三級醫院的處方量顯著增加，有助於提高患者的可及性和長期使用率。- 由於生產規模擴大和成本效率的提升，公司毛利率提升至54.2%，高於去年同期的46.5%。- 在銷售額同比增長112%的情況下，報告期內公司銷售費用為6420萬元，與去年同期相比僅增長5%，報告期內銷售費用約占總收入的29.5%，顯著低於去年同期的59.5%。這是因為，2025年上半年銷售費用構成與2024年同期相比發生了顯著變化：由公司在中國承擔华堂宁(R)的獨家商業化責任而直接產生銷售費用，而無需再向原商業化合作夥伴支付推廣費用。這反映出公司顯著的盈利向好趨勢，也表明了公司的業務戰略，即通過控制與华堂宁(R)商業化直接相關的銷售費用，以及最大限度地提高生產效率，來優化盈利能力。- 與拜耳終止獨家推廣服務協議後，公司確認一次性遞延收入12.435億元，向自主驅動增長轉型。華領醫藥首次實現半年稅前利潤11.839億元，這是華領醫藥邁向可持續盈利的關鍵里程碑。- 截至2025年6月30日，現金餘額為10.228億元，為公司未來的研發和商業化舉措奠定了堅實基礎。臨床研究持續深入，新證據支撐治療潛力- 公司正在推進多項上市後研究，以評估多格列艾汀在不同患者群體中的長期安全性和有效性，包括單藥治療以及與其它已經獲批的熱門降糖藥，如GLP-1受體激動劑、胰島素、DPP-4抑制劑和SGLT-2抑制劑的聯合用藥。這些研究正在為血糖控制、認知改善和糖尿病緩解潛力等提供新的臨床依據。- 公司正在開展多格列艾汀上市後真實世界研究（BLOOM），在全國80家中心納入2000例2型糖尿病患者，目前已完成1000余例患者的1年隨訪。在真實世界環境中，BLOOM研究進一步證明了多格列艾汀的廣泛適用性和安全性。在臨床用藥中，接受多格列艾汀治療的患者往往存在多種合並症，包括各種心血管和腎臟疾病等，並且正在接受多種伴隨藥物治療。除二甲雙胍外，超過60%的患者在使用多格列艾汀的同時，還聯合使用了SGLT-2抑制劑、胰島素、GLP-1受體激動劑或DPP-4抑制劑等其它降糖藥。無論是單藥治療還是聯合用藥，多格列艾汀普遍表現出良好的耐受性，安全性特徵也與先前的臨床研究資料保持一致。- 在2025年美國糖尿病協會（ADA）科學年會上，公司公佈了多格列艾汀的新研究資料，進一步闡明其作為疾病修飾療法的作用機制，關於多格列艾汀作為GKA藥物的新作用機制的相關成果已發表於《糖尿病》（Diabetes）雜誌上。研發管線與未來展望- 公司已在中國香港提交多格列艾汀75mg（商品名：華領片TM，MYHOMSIS(R)）的註冊申請，旨在擴大在大中華區和東南亞的業務版圖。- 公司正在通過開發二甲雙胍和多格列艾汀的固定複方製劑拓展產品管線，用於服用高劑量二甲雙胍（>每日1500mg）仍無法控制血糖的患者，此前的DAWN臨床研究顯示，多格列艾汀聯合二甲雙胍用藥可使患者的糖化血紅蛋白（HbA1c）降低超過1%，餐後血糖降低超過5mmol/L，低血糖發生率僅為0.8%。該血糖控制水準表明，多格列艾汀-二甲雙胍固定劑量複方製劑作為口服降糖藥具有強大的潛在需求。2025年8月，公司已完成IND前資料提交，預計於2026 年初啟動生物等效性（BE）研究。- 通過收集真實世界證據以及在動物模型中開展概念驗證研究，公司正在推進多格列艾汀與GLP-1受體激動劑、DPP-4製劑和SGLT-2抑制劑的聯合用藥。多格列艾汀與這些藥物之間的協同作用有望將其適應症擴展到肥胖症、代謝相關脂肪性肝炎（MASH）等其它代謝紊亂疾病領域。- 公司將繼續加強與國際領先的研究機構的合作。由華領醫藥支持的一項研究者發起的I 期臨床研究正在賓夕法尼亞大學進行，旨在評估多格列艾汀在囊性纖維化相關糖尿病（CFRD）患者中的療效和安全性，該試驗已獲得美國食品藥品監督管理局（FDA）的批准。- 公司將繼續致力於開發糖尿病預防、代謝紊亂相關神經退行性疾病領域的治療機遇，最終找到一種新的方法來延長人類的健康壽命。- 公司將繼續投資於數字技術平台，以在各個職能部門之間創造協同效應，並利用人工智慧技術提升品牌機遇。- 公司將繼續自主推進多格列艾汀和第二代GKA的研發，並與學術和戰略合作夥伴共同開展相關工作。公司正在推進多格列艾汀在香港的註冊，並繼續在東南亞和"一帶一路"國家尋求合作夥伴。基於美國I期單劑量遞增研究的初步成功，公司計劃於2025年底或2026年初啟動多劑量遞增I期研究，從而繼續推動第二代GKA在全球市場的業務發展。財務摘要截至2025年6月30日- 公司銀行結餘及現金約人民幣10.228億元- 總營收約2.174 億元，同比增長112%，华堂宁(R)銷量達176.4萬盒，同比增長108%- 毛利約1.178億元，同比增長147%，毛利率約54.2%，同比增長7.7個百分點- 其他收入約12.546億元，其中拜耳一次性遞延收入為12.435億元- 總開支約1.871億元，其中研發開支約6580萬元- 稅前利潤約11.839億元，同比增長932%前瞻性聲明本文包含有關華領醫藥以及產品未來預期、計劃和前景的陳述。該等前瞻性陳述僅與本文作出該陳述當日的事件或資料有關，可能因未來發展而出現變動。除法律規定外，於作出前瞻性陳述當日之後，無論是否出現新資料、未來事件或其他情況，我們並無責任更新或公開修改任何前瞻性陳述及預料之外的事件。請仔細閱讀本文並理解，由於各種風險、不確定性或其他法定要求我們的實際未來業績或表現可能與預期有重大差異。關於華領華領醫藥（"本公司"）是一家總部位於中國上海的創新藥物研發和商業化公司，在美國、中國香港設立了公司。華領醫藥專注於未被滿足的醫療需求，為全球患者開發全新療法。華領醫藥匯聚全球醫藥行業高素質人才，融合全球創新技術，依託全球優勢資源，研究開發突破性的技術和產品，引領全球糖尿病醫療創新。公司核心產品华堂宁(R)（多格列艾汀片）以葡萄糖感測器葡萄糖激酶為靶點，提升2型糖尿病患者的葡萄糖敏感性，改善患者血糖穩態失調。2022年9月30日，华堂宁(R)已獲得中國國家藥品監督管理局（NMPA）的上市批准，用於單獨用藥或者與二甲雙胍聯合用藥，治療成人2型糖尿病。對於腎功能不全患者，無需調整劑量，是一款可用於腎功能損傷的2型糖尿病患者的口服降糖藥物。詳情垂詢華領醫藥網址：www.huamedicine.com投資者電郵：ir@huamedicine.com媒體電郵：pr@huamedicine.com新聞免責聲明本材料，如為上下文論述的準確性和完整性，提及在中國上市的產品相關資訊的，特別是標識或要求，應遵循中國監管機構批准的相關檔。另外，相關資訊不應被解讀為對任何藥物或者診療方案的推薦或者宣傳，亦不應替代任何醫療衛生專業人士的醫療建議，涉及醫療的相關事宜務必諮詢醫療衛生專業人士。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2025-08-28

Hua Medicine Announces 2025 Interim Results

- Sales of HuaTangNing increased by 108% year-on-year, with net sales increasing by 112% year-on-year. Reimbursement coverage continued to expand, with a significant increase in prescription volumes across Tier 2 and Tier 3 hospitals, as our comprehensive commercialization strategy achieved significant results.- Following the termination of the exclusive promotion service agreement with Bayer, the Company recognized a one-time release of previously deferred income of RMB 1,243.5 million, achieving a profit of RMB 1,183.9 million for the first half of the year. This is the Company's first profit during the performance period.- A real-world study (BLOOM) involving 80 centers and 2,000 patients with Type 2 diabetes conducted in China further demonstrated the broad applicability and safety of dorzagliatin.- A registration application has been submitted in Hong Kong for Dorzagliatin 75mg (brand name: MYHOMSIS®), aiming to extend its presence across Greater China and Southeast Asia.- Gross profit margin improved significantly, as production scale and operational efficiency continued to be optimized.SHANGHAI, Aug 28, 2025 - (ACN Newswire via SeaPRwire.com) - Hua Medicine (the “Company”, HKEx: 2552) announced the unaudited consolidated results of the Company and its subsidiaries for the six months ended June 30, 2025 (the “Reporting Period”), as well as the Company's business progress during the first half of the year and future outlook. During the Reporting Period, the commercialization of the Company's core product, HuaTangNing (dorzagliatin tablets), accelerated. The Company’s independent operational capabilities improved significantly. R&D progress advanced smoothly and the Company’s financial performance achieved breakthrough growth, laying a solid foundation for long-term sustainable development.  “The first half of 2025 was a critical stage in Hua Medicine’s transformation and development. Following the full takeover of the commercialization of HuaTangNing, the Company achieved double-digit growth in sales and revenue through its independently established sales team, thereby validating the effectiveness of the new business model. We have also submitted a new drug application in Hong Kong, China, laying the foundation for dorzagliatin to expand from China to Southeast Asia and the global market,” said Dr. Li Chen, founder and CEO of Hua Medicine, “Dorzagliatin has continued to demonstrate broad therapeutic potential in real-world studies, and new evidence has been found in basic research regarding diabetes remission, cognitive improvement, lipid improvement, and muscle gain, further consolidating Hua Medicine’s global leadership in GKA research and development and treatment. In the future, Hua Medicine will continue to focus on diabetes and the entire field of metabolic diseases, driving innovation through research and development and market expansion to bring the benefits of China's original innovative drugs to more patients worldwide.”   Business Highlights and Operational ProgressCommercialization transformation achieved remarkable results, with doubling of sales and profits.- Effective from January 1, 2025, the Company terminated its exclusive promotion service agreement with Bayer and fully took over the commercialization of HuaTangNing (å''å ‚å®'®) in China. During the Reporting Period, with unit prices remaining consistent with the same period in 2024, sales of HuaTangNing reached 1,764,000 packs, a year-on-year increase of 108%. Net sales reached RMB217.4 million, a year-on-year increase of 112%. Leveraging strong commercial execution and continuously improving operational efficiency, the Company is moving toward profitability. Hua Medicine has successfully transitioned to a fully independent commercialization phase, confirming growing market demand and the efficient execution capabilities of its independent sales team.- Sales of HuaTangNing continued to benefit from its inclusion in China’s National Reimbursement Drug List (NRDL), which took effect in January 2024. Reimbursement coverage under the NRDL has significantly increased accessibility, especially in Tier 2 and Tier 3 hospitals, and played a critical role in accelerating patient adoption.- Due to expanded production scale and improved cost efficiency, the Company's gross profit margin increased to 54.2%, higher than 46.5% in the same period last year.- With sales revenue growing 112% year-on-year, the Company's sales expenses during the Reporting Period were RMB64.2 million for the six months ended June 30, 2025, growing only 5% compared to the same period last year. The composition of our selling expenses for the six months ended June 30, 2025 changed significantly from the same period in 2024 due to the Company incurring selling expenses directly as a result of assuming sole commercialization responsibilities for HuaTangNing in China, while no longer owing promotion expenses to the former commercialization partner. These figures also reflect a significant positive trend towards profitability and demonstrate our business strategy of optimizing profitability by controlling commercialization sales expenses of HuaTangNing and maximizing production efficiency, where our selling expenses in the first half of 2025 represent approximately 29.5% of total revenue whereas in the first half of 2024, our selling expenses represented approximately 59.5% of total revenue. - After terminating the exclusive promotion service agreement with Bayer, the Company recognized a one-time release of previously deferred income of RMB1,243.5 million and transitioned to self-driven growth. Hua Medicine achieved a pre-tax profit of RMB 1,183.9 million for the first half of the year, marking a key milestone of Hua Medicine towards sustainable profitability.- As of June 30, 2025, the cash balance was RMB1,022.8 million, laying a solid foundation for the Company's future R&D and commercialization initiatives.Clinical research continues to deepen, with new evidence supporting treatment potential- Hua Medicine is conducting multiple post-marketing studies to evaluate the long-term safety and effectiveness of dorzagliatin across diverse patient populations, both in monotherapy as well as in combination with other popular approved anti-diabetic drugs, such as GLP-1 receptor agonists, insulin, DPP-IV inhibitors and SGLT-2 inhibitors. These studies are generating new clinical insights into glucose control, cognitive outcomes, and potential for diabetes remission.- A real-world study (BLOOM) is being conducted in 2,000 patients with Type 2 diabetes across 80 centers in China. BLOOM has already completed one-year follow-up in over 1,000 participants. In the real-world setting, BLOOM further demonstrates the broad applicability and safety of dorzagliatin. Patients receiving dorzagliatin in routine clinical practice present with a heterogeneous mix of comorbidities, including various cardiovascular and renal disorders and are managed with multiple concomitant medications. In addition to metformin, more than 60% of patients concurrently used SGLT-2 inhibitors, insulin, GLP-1 receptor agonists, or DPP-IV inhibitors and other anti-diabetic drugs with dorzagliatin. In monotherapy or in combination with the popular above-mentioned anti-diabetic drugs, dorzagliatin was generally well tolerated, and its safety profile remained consistent with previously established data.- Hua Medicine presented new data at the 2025 American Diabetes Association (ADA) conference, reinforcing dorzagliatin’s potential as a disease-modifying therapy. Insights into the novel mechanism of action (MOA) of dorzagliatin as a therapeutic GKA were published in Diabetes.Research and Development Pipeline and Future Outlook- The company filed its application for registration of dorzagliatin 75mg in Hong Kong as MYHOMSIS®, aiming to extend its presence across Greater China and southeast Asia.- We are continuing expansion on our product pipeline through development of fixed dose combination of metformin and dorzagliatin for patients who have failed to control blood glucose levels while using high dose metformin (daily dose>1500 mg). In the loose dose combination study-DAWN Trial, dorzagliatin add-on to metformin provided HbA1c reduction of greater than 1% and post meal glucose reduction of greater than 5 mmol/L. These desirable glycemic control levels coupled with a very safe 0.8% hypoglycemic rate would suggest strong potential demand for a branded oral anti-diabetic medication using a convenient fixed dose combination of dorzagliatin and metformin. The Pre-IND submission has been achieved in August 2025, and we are expected to initiate the bioequivalence study in early 2026.- We are also advancing the combination of dorzagliatin with GLP-1RA, SGLT-2 inhibitors, insulin and DPP-IV inhibitors through combined effects in collecting real world evidence and proof of concept studies in animal models. The synergy between dorzagliatin with these agents has the potential to expand our indications into other diseases in metabolic disorders, such as obesity and MASH.- We continue to enhance our collaborations with leading international research institutions. A Phase I investigator-initiated trial supported by the Group and conducted at the University of Pennsylvania – designed to evaluate the efficacy and safety of dorzagliatin in patients with cystic fibrosis-related diabetes (CFRD) – has received clearance from the U.S. FDA.- We will continue our engagement in diabetes prevention, opportunities in metabolic disorder related neurodegeneration disease and eventually find a new way to increase healthy life span and longevity in humans.- We continue to invest in digital technology platforms to create synergies across functions and enhance branding opportunities using AI technology.- As illustrated in our product pipeline chart, we will continue to advance our R&D efforts for both dorzagliatin and our 2nd generation GKA on our own as well as in collaboration with academic and strategic partners. We are working on the registration of dorzagliatin in Hong Kong and continue to seek partnerships in Southeast Asia and Belt and Road nations. In addition, we will continue our business development efforts on our 2nd generation GKA for the global markets based on the initial success of the Phase 1 single-ascending dose study in the United States and the initiation of our Phase 1 multiple ascending dose study planned for late 2025 or early 2026.Financial SummaryAs of June 30, 2025- Bank balances and cash amounted to approximately RMB 1,022.8 million.- Total revenue was approximately RMB217.4 million, representing a year-on-year increase of 112%. Sales of HuaTangNing (å''å ‚å®'®) reached 1,764,000 packs, representing a year-on-year increase of 108%.- Total gross profit was approximately RMB117.8 million, representing a year-on-year increase of 147%. Gross margin was approximately 54.2%, increased by approximately 7.7 percentage points, as compared with the six months ended June 30, 2024.- Total other income amounted to approximately RMB1,254.6 million , of which Bayer's one-time release of previously deferred income was RMB1,243,5 million.- Total expenditures were approximately RMB187.1 million, of which research and development expenditure was approximately RMB65.8 million.- Profit before tax was approximately RMB1,183.9 million, representing  approximately 932% for the six months ended June 30, 2025Forward-Looking StatementsThis document contains statements regarding Hua Medicine’s future expectations, plans, and prospects for the Company and its products. These forward-looking statements pertain only to events or information as of the date they are made and may change due to future developments. Unless required by law, we are not obligated to update or publicly revise any forward-looking statements or unexpected events after the date of such statements, regardless of new information, future events, or other circumstances. Please read this document carefully and understand that our actual future performance or results may differ materially from expectations due to various risks, uncertainties, or other legal requirements.About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment.For more informationHua MedicineWebsite: www.huamedicine.comInvestors E-mail: ir@huamedicine.comMedia E-mail: pr@huamedicine.comPress DisclaimerFor accuracy and completeness in context, information related to products marketed in China in this material, especially those identified or required, should comply with documents approved by Chinese regulatory authorities.Additionally, such information should not be interpreted as a recommendation or promotion of any drug or treatment, nor should it replace medical advice from healthcare professionals. For medical-related matters, please consult a healthcare professional. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2025-08-28

陽光保險中期業績發佈：持續深化「知心陽光」戰略內涵  各項業務穩健增長

香港，2025年8月28日 - (亞太商訊 via SeaPRwire.com) - 此前，民營險企陽光保險（6963.HK）發佈2025年中期業績，數據顯示，2025年上半年，公司實現總保費收入808.1億元，同比增長5.7%；歸屬於母公司股東的淨利潤33.9億元，同比增長7.8%；集團內含價值1,284.9億元，較上年末增長11.0%，公司各項業務保持穩健增長。陽光保險成立於2005年，轉眼間，陽光保險已走過20年的歷程。在這20年的征程中，公司不斷拓展業務領域，從財產險到人壽險，從健康險到意外險，陽光保險的產品線日益豐富，為不同客戶群體提供了多樣化的保險選擇。加大產品與服務體系佈局 全面提升客戶服務體驗在壽險方面，業績公告顯示，2025年上半年，陽光人壽持續深化「知心陽光」戰略內涵，實施廣泛的客戶需求調研，加大產品與服務體系的佈局，優化客戶服務體驗。上半年中高客戶經營穩步提升，有效保單累計首年標準保費15萬元及以上的客戶數增長20.5%，有效保單累計首年標準保費5萬元及以上的客戶數增長17.5%。同時，公告表示陽光人壽緊抓新經濟週期與人口老齡化機遇，在養老金融領域豐富個養產品矩陣，在健康保障方面重點佈局醫保目錄外的創新藥、特藥保障功能，滿足醫改背景下客戶差異化的保障需求。同時，優化升級財富管理功能產品，構建涵蓋四大類、13款浮動收益產品的組合，滿足新經濟週期下客戶多元化的財富管理需求。此外，公司公告介紹了陽光人壽的「知心陽光」服務體系建設進度。在居家養老領域，陽光人壽以適合老年人且使用便捷的「小陽智能屏」為操作載體，為客戶提供即時、全面、安心的健康及生活類服務，目前已覆蓋全國31個省級行政區233個城市。在健康醫療領域，構建「預防－診療－康復」全週期管理閉環，有效解決醫療資源可及性、服務連續性等核心問題。在教育領域，構建「海外留學+國內升學」雙輪驅動模式，形成覆蓋全學齡段的教育服務體系。在不斷拓展線下服務的同時，陽光人壽積極佈局線上服務，全面提升客戶體驗。數據顯示，2025年上半年，「我家陽光」APP完成30項核心功能的新增與優化，截至2025年6月底，「我家陽光」APP累計註冊用戶突破619.2萬，較上年末增長7.3%。同時，公司聚焦銀髮群體線下業務辦理流程繁瑣、智能工具使用存在障礙等保單服務痛點，創新推出「陽光雲櫃面」遠程智能服務平台，切實保障了銀髮群體的金融消費權益。深入洞察客戶需求 升級差異化經營體系在財險方面，業績公告表示2025年上半年，陽光財險持續優化服務，深入洞察客戶需求，升級客群差異化經營體系。通過構建「六維」客戶畫像和「四性」服務評價模型，打造全流程智能化閉環服務體系，實現「千人千面」的個性化服務。同時，創新推出多款短期健康險升級版產品，為單一車險客戶提供綜合保險保障。2025年上半年，高頻服務客戶滿意度均在9分以上（滿分10分），個人車險客戶非車險產品購買比例達到60.9%，同比提升5.4個百分點。團體客戶方面，持續深化“夥伴行動”風險管理服務落地，建立針對整體服務能力評價的ABCD分級體系和針對專業技術能力評價的L1-L4分級標準，促進公司風險管理服務能力和服務品質的提升。2025年上半年，為1.8萬家企業客戶提供覆蓋L1-L4級的各類風險管理服務。2025年上半年，陽光保險通過持續優化產品與服務體系，積極拓展業務領域，在諸多領域取得了新進展。站在行業的新週期階段，未來，期待更多保險企業以客戶的需求為導向，不斷優化服務，提升品牌價值與客戶體驗，充分發揮出保險業經濟減震器與社會穩定器的職責。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2025-08-28

Shoucheng and IAT Join Forces to Drive ‘Robotics + Automobiles’

HONG KONG, Aug 28, 2025 - (ACN Newswire via SeaPRwire.com) - Shoucheng Holdings Limited (0697.HK, hereinafter referred to as “Shoucheng Holdings”), Beijing Shoucheng Robotics Technology Industry Co., Ltd. (hereinafter referred to as “Shoucheng Robotics”), IAT Automobile Technology Co., Ltd. (300825.SZ, hereinafter referred to as “IAT”), and Beijing IATROBOT Technology Co., Ltd. (hereinafter referred to as “IATROBOT”) officially signed a strategic cooperation framework agreement.The four parties will leverage their respective strengths to carry out comprehensive cooperation in technological innovation, application deployment, industry chain collaboration, and talent cultivation within the robotics sector, jointly accelerating the development of new business models in the “Robotics + Automobiles” field.I. Industry Background: Robotics Entering the Acceleration Phase of Application DeploymentAt present, the global robotics industry is in a stage of rapid development, with national strategies and policies being introduced intensively. On August 26, the State Council officially released the Opinions of the State Council on Deeply Implementing the “AI+” Initiative (Guo Fa [2025] No. 11), which explicitly calls for promoting the extensive and in-depth integration of artificial intelligence with various industries and fields across the economy and society, and accelerating the formation of new models of intelligent economy and intelligent society characterized by human-machine collaboration, cross-industry integration, and co-creation.Under this national strategy, the robotics industry is shifting from “technological breakthroughs” to “application deployment.” Automobiles and robotics, as two highly complementary industries, are increasingly showing a trend of cross-sector integration. The cooperation between Shoucheng Holdings and IAT Group, under the dual drivers of favorable policy and strong market demand, will inject new momentum into robotics applications across key segments such as R&D, manufacturing, transportation, and mobility services.IAT is a leading enterprise in China’s automotive design field and the only independent automotive design company listed on the A-share market. The company provides full-process services ranging from complete vehicle R&D and design to core component manufacturing, while pursuing a globalization strategy of “technology + supply chain.” According to public information, IAT has served more than 80 clients and participated in the development of nearly 500 vehicle models. Its clients include major OEMs such as FAW, Dongfeng, BAIC, Geely, emerging EV brands, as well as joint-venture automakers. This highlights IAT’s strong OEM resources and delivery capabilities across the automotive value chain.At the same time, through its subsidiary — Beijing IATROBOT Technology Co., Ltd. — IAT has officially entered the robotics sector. IATROBOT is dedicated to building an integrated R&D, design, and simulation training platform, capable of supporting multi-scenario robotics development from simulation and testing to optimization. The company has already launched multiple R&D projects, including wheeled robots, underwater robots, drilling robots, and pet-care robots, demonstrating its potential in cross-scenario development and industry collaboration. The involvement of IATROBOT expands the scope of this cooperation beyond traditional automotive design, providing important support for the integration of robotics R&D, simulation, and automotive industrialization.By partnering with IAT and IATROBOT, Shoucheng will be able to embed robotics technologies deeply into the core stages of the automotive value chain, such as vehicle manufacturing, intelligent assembly, and production line testing. This will enable robots to truly enter the production line and accelerate industrial adoption. This strategic cooperation is not merely a technological connection — it leverages IAT’s extensive OEM client network to move robotics scenarios from “next-door demonstrations” directly into the “factory workshop,” bridging the crucial pathway between R&D validation and scaled industrial delivery.II. Key Areas of Cooperation: Balancing R&D Breakthroughs and Application DeploymentGuided by the State Council’s “AI+” Initiative, the four parties will anchor their collaboration on the full chain of “technology R&D — industrial application — ecosystem co-construction,” working together to drive industrial innovation. The cooperation will focus on the following areas to promote the deep integration of robotics and automobiles:(1) Technological Innovation and Joint R&DThe four parties will jointly build an integrated robotics R&D and simulation platform, drawing on the comprehensive R&D system of the automotive industry. The focus will be on achieving breakthroughs in key areas such as motion control, structural optimization, automotive-grade components, and large-scale manufacturing. Leveraging NVIDIA Isaac/Omniverse technology, the parties will co-develop an integrated simulation training platform that not only supports simulation of robotics applications in automotive R&D, manufacturing, and testing, but also enables cross-scenario simulations such as collaborative operations between autonomous driving vehicles and logistics robots.In addition, a mechanism for data and outcome sharing will be established: Shoucheng Holdings will provide operational data resources from transportation and mobility scenarios, while IAT will contribute expertise in automotive engineering and robotics R&D, together forming a complete closed loop spanning simulation — R&D — validation — production line application.(2) Priority Procurement and Synergy MechanismAcross R&D design, simulation training, complete machine and component supply, the four parties will adopt a priority procurement mechanism, under which signatories will be given preference as partners under equivalent conditions. Shoucheng Holdings and Shoucheng Robotics will focus on product promotion, distribution, and supporting services, while IAT and IATROBOT will concentrate on technology R&D, engineering validation, and customized whole-machine development.The parties will also work together to advance secondary development of robotic systems, ensuring optimal adaptation of robotics products to scenarios such as automotive production lines, intelligent assembly, and line testing. Through division of labor and collaborative mechanisms, a complementary cycle of product supply — technological innovation — application feedback will be established, accelerating the conversion of results and enhancing commercialization efficiency.(3) Talent DevelopmentLeveraging the research and industrial platforms of Shoucheng, IAT, and their partners, the four parties will jointly carry out technological problem-solving, simulation training, and application pilots, providing researchers and engineers with cross-industry, cross-scenario practical environments. Regular technical seminars and industry forums will be held, inviting experts and upstream and downstream enterprises to participate, thereby establishing a joint talent development mechanism. This initiative aims to cultivate a new generation of young researchers with both automotive engineering backgrounds and practical experience in robotics industrialization, laying a solid talent foundation for long-term growth.(4) Expanding Development HorizonsThe four parties will closely align with national strategies for “AI+” and robotics industry development, with a focus on scaling up “Robotics + Automobiles” applications in R&D, manufacturing, testing, and mobility services. Building on this foundation, the cooperation will gradually extend into broader fields such as smart transportation, intelligent manufacturing, healthcare, education, and public services, covering the design, R&D, production, testing, and commercialization of robots and core components. At the same time, by integrating capital and industry, the parties will drive coordinated upgrades across the value chain, ultimately forming a full-cycle closed loop from R&D validation to large-scale application. This will create a demonstrative “Robotics + Automobiles” application matrix, achieving mutual benefits and long-term value creation.III. Strategic Significance: Establishing a New Benchmark for Robotics ApplicationsThe greatest value of the robotics industry lies in real-world applications, and “Robotics + Automobiles” stands out as one of the most promising and high-potential application directions. From complete vehicle R&D to intelligent manufacturing, from traffic scheduling to smart mobility, robots will create tremendous value across the entire automotive value chain.Shoucheng Holdings, leveraging its capital platform, ecosystem resources, and industrial fund advantages, has invested in leading domestic enterprises such as Unitree Robotics, Galbot, Noetix Robotics, Galaxea-AI, and Booster Robotics, equipping it with the capability to integrate frontier technologies. Shoucheng Robotics has established collaborations with hundreds of high-quality upstream and downstream enterprises, making it one of the most comprehensive resource-linking platforms in China. IAT and IATROBOT, in turn, bring mature automotive engineering systems into robotics R&D and industrialization. Together, the combined strengths of both sides will form a complete pathway of “R&D — iteration — application — scale-up.”By joining forces with IAT, Shoucheng will further integrate its scenario resources and industrial ecosystem with IAT’s expertise in vehicle R&D, engineering capabilities, and industrialization experience. Over the next one to two years, the cooperation will focus on the deep integration of “Robotics + Automobiles,” taking the lead in demonstrating large-scale applications across vehicle R&D, production and manufacturing, smart transportation, and mobility services. This will accelerate the transition of robotics from laboratories to industrialization and large-scale deployment, creating a demonstrative “Robotics + Automobiles” application matrix. At the same time, the cooperation will also look to the international market, bringing Chinese solutions to the global stage, fostering new quality productivity, and generating long-term value for shareholders.Posted by All Way Success Company Limited for Shoucheng Holdings www.shouchengholdings.com [HKSE:0697, FRA:SHVA, OTCPK:SHNHF] Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2025-08-28

首程攜手阿爾特簽署戰略合作協議 共推「機器人+汽車」應用產業化落地

香港，2025年8月28日 - (亞太商訊 via SeaPRwire.com) - 2025年8月，北京--首程控股有限公司（0697.HK，以下簡稱「首程控股」）、北京首程機器人科技產業有限公司（以下簡稱「首程機器人」）、阿爾特汽車技術股份有限公司（300825.SZ，以下簡稱「阿爾特」）、北京阿爾瑞特智能機器人科技有限公司（以下簡稱「阿爾瑞特」）正式簽署戰略合作框架協議。四方將充分發揮各自優勢，圍繞機器人產業的技術創新、應用落地、產業鏈協同與人才培養，展開全方位合作，推動「機器人+汽車」應用新業態加速發展。一、產業背景：機器人進入應用落地加速期當前，全球機器人產業正處於高速發展階段，國家戰略和政策密集出台。8月26日，國務院正式發佈《國務院關於深入實施「人工智能+」行動的意見》（國發〔2025〕11號），明確提出要推動人工智能與經濟社會各行業各領域的廣泛深度融合，加快形成人機協同、跨界融合、共創分享的智慧經濟和智慧社會新形態。在這一國家戰略指引下，機器人產業正從「技術突破」邁向「應用落地」。汽車與機器人作為兩個高度契合的產業，正逐漸呈現跨界融合趨勢。此次首程控股與阿爾特集團的合作，將在政策東風與市場需求的雙重驅動下，為機器人在研發、製造、交通和出行服務等關鍵環節的應用注入新動能。阿爾特是中國汽車設計領域的領軍企業，也是A股市場唯一的獨立汽車設計上市公司，具備整車研發設計與核心零部件製造的全流程服務能力，並踐行「技術+供應鏈」的國際化戰略。據公開資訊，公司累計服務超過80家客戶，參與開發近500款車型，客戶涵蓋一汽、東風、北汽、吉利、新勢力品牌與合資企業等主機廠類型。這意味著阿爾特在汽車產業鏈中擁有深厚的主機廠資源與交付能力。與此同時，阿爾特通過控股子公司--北京阿爾瑞特智能機器人科技有限公司，已正式開闢機器人新賽道。阿爾瑞特致力於打造一體化研發設計與仿真訓練平台，能夠為多場景機器人開發提供從仿真、測試到優化的全流程支撐；目前已啟動輪式機器人、水下機器人、鑽井機器人和寵物洗護機器人等多個研發項目，體現了其跨場景研發和產業協同的潛力。阿爾瑞特的加入，使本次合作不僅侷限於傳統汽車設計層面的協作，更在機器人研發、仿真與汽車產業化融合方面提供了重要支撐。與阿爾特及阿爾瑞特的合作，將幫助首程把機器人技術深度嵌入汽車產業鏈的核心環節，如整車製造、智能裝配與產線測試，使機器人真正進入產線、加速產業應用。這一戰略合作不只是一種技術對接，更是借助阿爾特在主機廠客戶群體中的資源網絡，將機器人場景從「隔壁展示」一步推向「生產車間」，連接研發驗證與規模化交付的關鍵路徑。二、合作重點：研發突破與應用落地並舉在國務院「人工智能+」行動政策引領下，四方將立足「技術研發-產業應用-生態共建」全鏈條，協同推進產業創新，重點在以下方向展開合作，助力機器人與汽車深度融合：（一）技術創新與聯合研發四方將聯合建設機器人一體化研發與仿真平台，借鑒汽車行業的完整研發體系，重點在運動控制、結構優化、車規級零部件和規模化製造等關鍵環節實現突破。同時，依託 NVIDIA Isaac/Omniverse 技術，共同打造一體化仿真訓練平台，不僅支援機器人在汽車研發、製造和測試中的應用模擬，還可開展智能駕駛車輛與物流機器人協同作業等跨場景模擬。雙方還將建立數據與成果共享機制：首程控股提供來自交通、出行等運營環節的數據資源，阿爾特輸出汽車工程和機器人研發經驗，形成從仿真-研發-驗證-產線應用的完整閉環。（二）優先採購與協同機制在研發設計、仿真訓練、整機和零部件供應等環節，四方將實行優先採購機制，在同等條件下優先選擇協議方為合作夥伴。首程控股與首程機器人重點提供產品推廣、代理及配套服務；阿爾特與阿爾瑞特聚焦於技術研發、工程化驗證和客製化整機開發。各方將協同推進機器人本體二次開發，確保機器人產品在汽車生產線、智能裝配和產線檢測等場景下實現最佳適配。通過分工協作，形成產品供給-技術創新-應用反饋的互補格局，加快成果轉化，提升商業化效率。（三）人才培養依託首程、阿爾特及其合作夥伴的科研與產業平台，四方將聯合開展技術攻關、仿真訓練與應用試點，為科研人員和工程師提供跨行業、跨場景的實踐環境。同時，定期舉辦技術研討會和產業論壇，邀請行業專家和上下游企業參與，建立聯合人才培養機制，打造一批兼具汽車工程背景與機器人產業化實踐經驗的青年科研人才，夯實長期發展的人才基礎。（四）拓寬發展空間四方將深度對接國家「人工智能+」與機器人產業發展戰略，重點推動「機器人+汽車」在研發、製造、測試和出行服務環節的規模化應用。在此基礎上，合作還將逐步延展至智慧交通、智能製造、醫療健康、教育、公共服務等更廣闊的領域，涵蓋機器人及核心零部件的設計、研發、生產、測試和商業化服務。同時，結合資本與產業的聯動，推動產業鏈上下游協同升級，最終形成從研發驗證到規模化應用的全鏈條閉環，打造具有示範效應的「機器人+汽車」應用矩陣，實現互利共贏和長期價值創造。三、戰略意義：打造機器人應用新標杆機器人產業的最大價值在於應用落地，而「機器人+汽車」正是最具潛力和爆發力的應用方向之一。從整車研發到智能製造，從交通調度到智慧出行，機器人將在汽車全產業鏈環節展現巨大價值。首程控股憑藉資本平台、生態資源與產業基金優勢，已投資宇樹科技、銀河通用、松延動力、星海圖、加速進化等國內頭部企業，具備前沿技術的整合能力；首程機器人則與上百家上下游優質企業建立合作，成為國內鏈接資源最全面的平台之一。阿爾特與阿爾瑞特則將汽車領域成熟的工程體系遷移至機器人研發與產業化。雙方優勢疊加，構建起「研發-迭代-應用-規模化」的完整路徑。此次攜手阿爾特，將進一步把首程的場景資源與產業生態，與阿爾特在整車研發、工程化能力與產業化經驗深度結合。未來1-2年，合作將聚焦「機器人+汽車」的深度融合，率先在汽車研發、生產製造、智慧交通與出行服務等環節實現規模化應用示範，推動機器人從實驗室走向產業化、規模化，加速形成具備示範效應的「機器人+汽車」應用矩陣。與此同時，合作也將放眼國際市場，推動中國方案走向全球，培育新質生產力，為股東創造長期價值。Posted by All Way Success Company Limited for Shoucheng Holdings www.shouchengholdings.com [HKSE:0697, FRA:SHVA, OTCPK:SHNHF] Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2025-08-28

陽光保險中期業績出爐：二十年穩健成長 科技驅動未來

香港，2025年8月28日 - (亞太商訊 via SeaPRwire.com) - 2025年，陽光保險（6963.HK）成立20周年。其最新發佈的2025年中期業績顯示，上半年實現總保費收入808.1億元，同比增長5.7%；歸母淨利潤33.9億元，同比增長7.8%；內含價值達到1,284.9億元，較上年末增長11.0%；有效客戶數超過3,011萬。堅守價值導向 價值發展能力與韌性不斷增強創業容易守業難，保險行業更是如此。陽光保險卻實現業務規模的有質增長。從初創到上市，再到截至2025年6月30日，資產規模已達到6256億元。2025年上半年，陽光人壽以夯實利源基礎和資產負債匹配為核心任務，持續強化「三差」管理，深化實施「一身兩翼」戰略，堅定推進產品結構和銷售隊伍轉型。壽險業務總保費收入554.4億元，同比增長7.1%，新業務價值達40.1億元，同比增長47.3%；壽險內含價值突破1,062億元 ，較上年末增長13.8%。財險業務則在結構優化與盈利品質提升方面持續積累。2025年上半年，非車險保費占比達到50.6%，同比提升4.5個百分點；家用車保費在車險中佔同比提升3個百分點；承保綜合成本率優化至98.8%，承保利潤同比增長42.4%。資產管理業務以長期穩健、穿越週期為原則，持續提升資產與負債兩端科學、動態匹配的能力。上半年實現總投資收益107.0億元，年化總投資收益率4.0% ，年化綜合投資收益率5.1%。科技驅動 賦能主業高質量發展近年來，陽光保險在「科技陽光」戰略引領下，加快推進自身數智化轉型，為高質量發展賦能。2025年上半年，陽光保險深入推進「機器人工程」與「數據工程」，AI與大模型應用成果在多個核心場景落地。在銷售領域，陽光保險依託銷售輔助機器人、AI客戶經營助手的建設及數據賦能項目落地，幫助業務人員精准畫像客戶、匹配產品方案，顯著提升展業效能，AI客戶經營助手客戶滿意度達95%。在服務領域，陽光保險深化智能客服機器人建設，以智能化驅動客戶服務升級，遠程服務全流程無人辦理率達65%，智能服務滿意度達82%；通過「智慧應用+流程重塑」，創新打造理賠服務場景的企微機器人，大幅提升服務效率，降低服務成本。在管理領域，AI被應用於三差管理、財務管理、智慧定價、理賠管理等多個場景，全面提升運營效率，實現提質增效。展望下半年乃至更長週期，隨著銀髮經濟潛力釋放、居民保險需求升級，以及科技的持續演進，保險行業將迎來新的增長曲線。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2025-08-28

Sunshine Insurance Interim Results Released: Twenty Years of Steady Growth, Technology Driving the Future

HONG KONG, Aug 28, 2025 - (ACN Newswire via SeaPRwire.com) - 2025 is the 20th anniversary of Sunshine Insurance (6963.HK). Its latest released 2025 interim results show that in the first half of the year, the gross written premiums (“GWPs”) were RMB80.81 billion, representing a year-on-year increase of 5.7%; the net profit attributable to the parent was RMB3.39 billion, representing a year-on-year increase of 7.8%; the embedded value reached RMB128.49 billion, up 11.0% from the end of the previous year; and the number of active customers exceeded 30.11 million.Adhering to a Value-Oriented Approach, the Ability and Resilience for Value Development Continued to StrengthenStarting a business is easy, but sustaining it is difficult, and this is especially true in the insurance industry. However, Sunshine Insurance has achieved quality growth in its business scale. From its startup phase to listing, and as of 30 June 2025, its asset scale has reached RMB625.6 billion.In the first half of 2025, Sunshine Life focused on consolidating the foundation of profit sources and asset-liability matching as its core tasks, continuously strengthening the management of the “three margins ”, deepening the implementation of the “One Body, Two Wings ” strategy, and resolutely advancing the transformation of product structure and sales team. The GWPs of life insurance business were RMB55.44 billion, representing a year-on-year increase of 7.1%, and the value of new business was RMB4.01 billion, representing a year-on-year increase of 47.3%. The embedded value of life insurance exceeded RMB106.2 billion, up 13.8% from the end of the previous year.The structure of the property and casualty insurance business continued to optimize with steady improvement in profitability. In the first half of 2025, the proportion of non-automobile insurance premiums was 50.6%, representing a year-on-year increase of 4.5 percentage points. The household auto premiums to the automobile insurance rose by 3 percentage points. The underwriting combined ratio improved to 98.8% and underwriting profit increased by 42.4% year-on-year.The asset management business adheres to the principles of long-term stability and resilience across cycles, continuously enhancing its ability to achieve scientific and dynamic matching between assets and liabilities. In the first half of the year, total investment income reached RMB10.70 billion, with an annualized total investment yield of 4.0% and an annualized comprehensive investment yield of 5.1%.Tech Empowerment Fueled High-Quality Growth of Core BusinessesIn recent years, under the guidance of its “Technological Sunshine” strategy, Sunshine Insurance has accelerated its digital and intelligent transformation to empower high-quality development. In the first half of 2025, the Company made significant progress in advancing its “Robotics Initiative ” and “Data Engineering Program ,” with AI and large model applications being successfully implemented across multiple core business scenarios.In the sales sector, by deploying sales-assistance robots and AI customer management assistants while implementing data empowerment programs, Sunshine Insurance achieved measurable improvements in operation efficiency by delivering precise customer profiling, optimally matched product solutions to the sales staffs. The customer satisfaction of AI customer management assistant reached 95%. In the service sector, Sunshine Insurance transformed customer service through intelligent solutions by enhancing our AI-powered service robots. Our intelligent services handled 65% of remote service processes without human intervention while achieving 82% customer satisfaction. Through our newly developed claims service robot, we combined smart applications with process reengineering and innovatively applied the robotic services to enterprise WeChat-based claim scenarios. This approach significantly improved service efficiency while reducing operational costs. In the field of management, AI has been applied to multiple scenarios including management of the “three margins”, financial management, intelligent pricing, and claims management, significantly enhancing operational efficiency and improving quality and productivity.Looking ahead to the second half of the year and beyond, as the potential of the silver economy is unlocked, residents’ demand for insurance continues to upgrade, and technology keeps advancing, the insurance industry is poised to embrace a new growth curve. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2025-08-28

GA-ASI Marks Another Aviation First with YFQ-42A CCA Flight Testing

SAN DIEGO, Aug 28, 2025 - (ACN Newswire via SeaPRwire.com) - The YFQ-42A Collaborative Combat Aircraft, designed and developed by General Atomics Aeronautical Systems, Inc. (GA-ASI), is now conducting flight testing in coordination with the U.S. Air Force. This historic achievement continues the company's rapid creation of new, jet-powered uncrewed platforms chartered by the U.S. Air Force (USAF) to achieve air dominance while being designed for rapid production, in large quantities, at an affordable price."What a great moment for the U.S. Air Force and for GA-ASI," said GA-ASI President David R. Alexander. "It's been our collaboration that enabled us to build and fly the YFQ-42A in just over a year. It's an incredible achievement and I salute the Air Force for its vision and I salute our development team for delivering yet another historic first for our company."The YFQ-42A is GA-ASI's newest uncrewed jet, focused on air-to-air semi-autonomous operation and based on the genus-species concept pioneered on the XQ-67A Off-Board Sensing Station (OBSS). Using state-of-the-art, model-based digital engineering, GA-ASI was able to accelerate its schedule while optimizing air dominance capabilities. YFQ-42's autonomy core has been trained across more than five years of flight testing using GA-ASI's jet-powered MQ-20 Avenger®, an aircraft no other company has. The integrated capabilities of a stealthy, air-to-air-focused uncrewed jet, combined with a learned AI autonomy core, provide warfighters with a definitive advantage in the future fight.The GA-ASI program has focused on creating a high-rate production environment that enables USAF to reach its goal of producing more than 1,000 CCAs on an accelerated timeline. Ground testing for YFQ-42A began in May.USAF selected GA-ASI in April 2024 to build and fly a fully production-representative Collaborative Combat Aircraft (CCA). In March, USAF designated the aircraft the YFQ-42A, with the "Y" indicating a production-representative aircraft ("Y" will be dropped upon entering production), "F" signifying a fighter aircraft, and "Q" denoting an uncrewed aircraft.GA-ASI has developed more than two dozen different types of uncrewed aircraft and delivered more than 1,200 units to customers, building more than 100 aircraft per year at its 5 million-square-foot manufacturing facility in Poway, Calif. GA-ASI aircraft have amassed nearly 9 million total flight hours; more than 50 GA-ASI aircraft are aloft around the world every minute of every day.About GA-ASIGeneral Atomics Aeronautical Systems, Inc., is the world's foremost builder of Unmanned Aircraft Systems (UAS). Logging nearly 9 million flight hours, the Predator® line of UAS has flown for over 30 years and includes MQ-9A Reaper®, MQ-1C Gray Eagle®, MQ-20 Avenger®, and MQ-9B SkyGuardian®/SeaGuardian®. The company is dedicated to providing long-endurance, multi-mission solutions that deliver persistent situational awareness and rapid strike.For more information, visit www.ga-asi.com.Avenger, EagleEye, Gray Eagle, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are trademarks of General Atomics Aeronautical Systems, Inc. registered in the United States and/or other countries.Contact InformationGA-ASI Media Relationsasi-mediarelations@ga-asi.com(858) 524-8101SOURCE: General Atomics Aeronautical Systems, Inc. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2025-08-28

GA-ASI 再創航空新紀錄：YFQ-42A CCA 飛行測試

聖地亞哥, 2025年8月28日 - (亞太商訊 via SeaPRwire.com) - 由美國通用原子航空系統公司（General Atomics Aeronautical Systems, Inc., GA-ASI）設計與研製的 YFQ-42A 協同作戰飛機（Collaborative Combat Aircraft, CCA），目前正與美國空軍協同進行飛行測試。 這項歷史性成就延續了該公司快速打造新一代噴射動力無人平台的腳步。這些平台由美國空軍（USAF）主導，旨在確保制空優勢，同時在設計上兼顧快速量產、大規模生產以及合理成本。GA-ASI 總裁 David R. Alexander 表示：「對美國空軍與 GA-ASI 而言，這是多麼重要的時刻！正因為彼此的合作，我們才能在僅僅一年多的時間內完成 YFQ-42A 的建造與首飛。這是驚人的成就，我要向空軍的遠見致敬，也要向我們的開發團隊致敬，因為他們再一次為公司締造了歷史性的首次突破。」YFQ-42A 是 GA-ASI 最新的無人噴射機，專注於空對空半自主作戰任務，並以 XQ-67A「離機感測站」（Off-Board Sensing Station, OBSS）所首創的「屬級-種級」（genus-species）概念為基礎。藉由先進的模型導向數位工程（model-based digital engineering），GA-ASI 不僅加速了研發時程，還最佳化了制空能力。YFQ-42 的自主核心，已透過 GA-ASI 獨家擁有的噴射動力 MQ-20 Avenger® 進行超過五年的飛行測試訓練。這種隱身性、專注於空對空的無人噴射機，加上經過學習的 AI 自主核心，將為未來戰場上的作戰人員提供決定性的優勢。GA-ASI 的計畫重點在於建立一個高產能的生產環境，使美國空軍能夠在加速時程下達成生產超過 1,000 架 CCA 的目標。YFQ-42A 的地面測試已於今年 5 月展開。美國空軍於 2024 年 4 月選定 GA-ASI 負責建造並試飛一架完全符合量產規格的協同作戰飛機（CCA）。同年 3 月，美國空軍將該機命名為 YFQ-42A，其中「Y」表示為量產代表機（進入量產後「Y」字將被移除）、「F」代表戰鬥機（Fighter）、「Q」則代表無人飛機（Uncrewed）。GA-ASI 至今已研製出二十多種不同型號的無人飛機，並已交付超過 1,200 架給各類客戶。該公司位於加州波威市（Poway, Calif.）的五百萬平方英尺製造工廠，每年生產超過 100 架飛機。GA-ASI 的飛機總飛行時數已接近九百萬小時；全球每天每分鐘都有超過 50 架 GA-ASI 飛機在空中執行任務。關於 GA-ASI通用原子航空系統公司（GA-ASI）是通用原子公司的子公司，致力於設計與製造成熟可靠的遠程駕駛航空系統（RPA）、雷達與電光及相關任務系統，包括 Predator® RPA 系列與 Lynx® 多模式雷達。GA-ASI 累積飛行時數超過 900 萬小時，提供具備長航時與任務能力的航空平台，並整合感測器與數據鏈系統，以實現持續態勢感知。公司亦研發多種感測器控制與圖像分析軟體，提供飛行員訓練與支援服務，並開發超材料天線。更多資訊請參閱：www.ga-asi.com  。Avenger、Gray Eagle、Lynx、Predator、Reaper、SeaGuardian 和 SkyGuardian 均為通用原子航空系統公司在美國及其他國家/地區註冊的商標。聯絡資訊GA-ASI 媒體聯絡asi-mediarelations@ga-asi.com(858) 524-8101來源：通用原子航空系統公司 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2025-08-28

奧克斯電氣港股招股：業績高速增長 全球化佈局釋放長期成長空間

香港，2025年8月28日 - (亞太商訊 via SeaPRwire.com) - 在資本市場，兼具規模效應與穩健盈利能力的「優質消費白馬」一直是投資者關注的重點。從家電龍頭到餐飲、醫藥，資本對於行業龍頭的長期偏好始終未變。8月25日，奥克斯電氣有限公司（「奥克斯電氣」，股份代号：2580.HK）正式啟動香港招股，為港股消費板塊再添重磅標的。作為全球空調市場前五企業（按 2024 年銷量統計）及家用空調全球第四品牌，奥克斯電氣憑藉三十餘年在空調領域的深耕，已構建起覆蓋研發、生產、銷售、服務的全產業鏈優勢。本次IPO，奥克斯電氣擬全球發售約2.07億股，按最高發售價17.42港元計算，奥克斯電氣募資總額約36.09億港元，預期於9月2日登陸港交所。創新驅動，增長動能強勁當前，空調行業正處於綠色轉型與消費升級的關鍵階段，智能化、節能化已成為新一輪增長的核心驅動力。奥克斯電氣多年來始終將研發與創新視為企業發展的內核，圍繞「節能、舒適、健康、智能」四大方向深耕產品研發，持續推動產品創新及升級迭代。其家用空調矩陣涵蓋掛機、櫃機、移動空調等品類，中央空調則在多連機、熱泵等領域不斷迭代，滿足不同消費層級與使用場景的需求。與此同時，公司在語音辨識、遠端控制等智能交互領域實現突破，以迎合全球碳中和目標與智能家居趨勢，持續提升市場滲透率。创新不仅体现在前端产品，更深植于产业链核心环节。奥克斯電氣通過与松下合作，共同研发压缩机等关键零部件，强化了在全产业链上的掌控力。截至2025年3月31日，奥克斯電氣在境內外取得註冊專利超過12,000項，其中發明專利超過2,800項，擁有2項國家CNAS實驗室認證，累計參與制定空調行業相關國家標準及行業標準超過160項，並承擔了多項重大專項科研項目，為其自身發展構建強大競爭壁壘。在強大創新實力驅動下，奥克斯電氣展現出強勁的增長動能。2022-2024年，公司收入從195.28億元增至297.59億元，複合年增長率23.4%；淨利潤從 14.42億元增至 29.10億元，複合年增長率37.8%，盈利質量扎實。同期，空調銷量年複合增長率達到30%，遠超行業4.6%的整體水平。這一強勁增長，充分反映了奥克斯電氣在產業轉型中的領先優勢。全球化賦能，海外業務成新增長引擎在中國市場穩居領先的同時，奥克斯電氣正通過全球化戰略持續拓展增長空間。公司於2019年在日本成立研發中心，並實現泰國生產基地投產，並從2023年起開始在馬來西亞、泰國、美國、阿聯酋、越南及沙特阿拉伯等地設立銷售公司和團隊，形成「生產—銷售—服務」全鏈條的本地化運營模式，更好服務全球市場。目前，奥克斯電氣業務已覆蓋150多個國家和地區。得益于国际化战略的深化，奥克斯電氣海外业务实现快速成长。2022年至2024年間，公司海外收入佔比從42.9%升至49.3%。2025年一季度，海外收入占比达到57.1%，超过国内市场，成为公司增长的核心引擎。在東南亞、中東等新興市場，憑藉高性價比產品與本地化服務，銷量增速尤為突出 —— 亞洲（不含中國）市場收入占比從2024 年的 24.7%，進一步提升至2025 年一季度的 31.5%，成為海外增長主力。從行業維度看，奥克斯電氣的長期增長邏輯清晰可辨。根據弗若斯特沙利文報告，全球空調市場規模超萬億元且預計在2024年-2028年保持 4.3% 的年複合增長率，東南亞等新興市場因滲透率低、消費升級需求旺盛，成為核心增長極，進一步推動全球空調市場的增長。奥克斯電氣憑藉技術創新構建產品競爭力，依託全球化佈局搶佔增量市場，疊加港股上市後募集資金對研發、產能及管道的進一步投入，有望在行業整合中持續提升全球份額。對於投資者而言，這家兼具技術壁壘與全球化視野的空調龍頭，正迎來價值釋放的關鍵視窗，其長期投資價值值得重點關注。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2025-08-28

CALB (3931.HK) Announces 2025 Interim Results

HONG KONG, Aug 28, 2025 - (ACN Newswire via SeaPRwire.com) - On August 27, CALB Group Co., Ltd. ("CALB" or "the Company," stock code: 3931.HK) announced its unaudited condensed consolidated interim results for the six months ended 30 June 2025 (the "Reporting Period"). During the Reporting Period, the Company delivered outstanding operational performance with revenue of RMB16,418.88 million, representing an increase of 31.7% compared to the same period last year, and realized a profit of RMB752.99 million, representing a year-on-year increase of 80.4%. In the first half of 2025, the Company showed strong profitability and resilience during the accelerated trend of transformation of global renewable energy development.According to SNE Research, the Company’s installed capacity of globally EV batteries in the first half of 2025 increased 22.7%, ranking third domestically and fourth globally, with the monthly installed capacity reaching 4.7GWh. The Company was particularly outstanding in the domestic passenger vehicle market with the market share hitting new highs in June and July, reaching 7.4% and 8.25%, respectively. In the energy storage sector, the Company's growth was even more rapid. According to InfoLink, the Company’s shipment in the first half of the year ranked fourth globally, achieving milestone development in the energy storage sector.Centered on continuous technological breakthroughs and with the launch of multiple major products, in the first half of 2025, the Company maintained its leadership in cutting-edge battery technology with the “UP” battery. At the same time, the Company’s 400Wh/kg solid-liquid hybrid battery is poised for mass production and commercial deployment, while significant progress has been made in the all-solid-state battery—including breakthroughs in R&D and the commissioning of a dedicated production line. CALB’s high-power lithium iron phosphate R46 large cylindrical battery is the first in the industry to achieve mass production and has successfully achieved mass production for the latest PHEV models from Geely and Dongfeng. At the same time, the Company’s next-generation lithium manganese LFP battery product achieves an energy density exceeding 210Wh/kg and will also go into mass production. With improved performance, the product can attain 10%- 80% charging within 15 minutes.In the passenger vehicle market, leveraging exceptional product capabilities, the Company achieved full entry into the world’s top three automakers, namely Volkswagen, Hyundai and Toyota. In the first half of 2025, its 800V 5C batteries achieved a monthly sales volume of over 20,000 packs, which will support models for XPeng, Ledao, Leapmotor, Audi, BAIC, and others, and the 800V 5C high-voltage NCM battery exclusively supports popular models such as XPeng’s new P7 with ultra-long range, helping XPeng’s new P7 create a new world record of driving 3,971km in 24 hours.In the commercial vehicle market, CALB has established a comprehensive product matrix architecture for “ZHIYUAN” batteries, covering all scenarios, all applications, and all capabilities. In the first half of year, the Company’s domestic commercial vehicle installed capacity has increased by 310% year-on-year. CALB is the first in the industry to launch a million-kilometer customized products for light trucks, significantly improving the quality assurance of battery systems and effectively enhancing product competitiveness in the market. Leveraging the outstanding recognition from the light truck field, the Company has established in-depth collaborations with customers such as Chery, Geely, Ruichi, Foton, Dongfeng, Changan, and King Long. In the heavy truck field, the Company has deeply cultivated the market through the scenario-based power consumption design and has achieved full-spectrum collaboration by partnering with customers such as Sinotruk, XCMG, SANY, Shaanxi Automobile, Jiefang, Dongfeng, Lingong, and Liugong.The Company has made significant breakthroughs in the international market, and its energy storage business achieved rapid growth in the first half of year. The 314Ah second-generation long-cycle energy storage cell can achieve an ultra-long service life of 15,000 cycles and high energy efficiency of over 96%, while achieving zero degradation in the first 1,000 cycles, earning high recognition from customers for both the product and delivery capabilities. In terms of the overseas market, the Company has successfully partnered with the largest power plant projects in Latin America and South Africa, entering the supplier lists of several leading developers and power grid companies. Meanwhile, the Company’s next-generation “ZHIJIU” of 588Ah and 600Ah+ large energy storage cells will scheduled for mass production within the year.In addition, the Company is the first in the industry to pass the eVTOL power battery manufacturing compliance review and supports the development of China’s low-altitude economy market by actively exploring emerging markets. At present, the R46 cylindrical battery cell with an energy density of 310Wh/kg is now in mass production for leading eVTOL customers in the industry. At the same time, CALB signed a deepened strategic cooperation agreement with GOVY, under which the two parties will carry out in-depth collaboration in the eVTOL sector and jointly promote the development of standardized eVTOL energy products.Overall, in the first half of the year, CALB focused on the strategy of consolidating its leadership in products and technologies, while accelerating the globalization of its production capacity layout. At present, its battery Pack plant in Thailand has been put into operation, while construction of the Portugal base officially commenced in the first quarter of 2025. Looking ahead, with the further improvement of industrial chain system, the Company is expected to leverage its cross-domain, cross-scenario dynamic storage product matrix to achieve deep synergy in its dynamic storage business, creating cutting-edge product capabilities across all scenarios. At the same time, the Company will continuously explore emerging markets such as rail transit, mining, low-altitude flight, and humanoid robots by offering high-safety, high-reliability, and high-performance product solutions. Furthermore, CALB will continue to advance the implementation of its “energy+” strategy, further consolidating its leading position in the global new energy industry.About CALBCALB is a new energy enterprise specializing in the research, production, sales, and market application development of lithium batteries, battery management systems, and related integrated products and lithium battery materials. As Battery Expert, we aim to build a comprehensive energy operation system, to provide complete product solutions and full life-cycle management for the new energy application market, represented by power and energy storage.Currently, CALB has completed an all-round layout in domestic by setting up industrial bases in Changzhou, Xiamen, Wuhan, Chengdu, Hefei, Jiangmen and Meishan. Meanwhile, CALB has set up bases in Europe and ASEAN, vigorously expanding the layout all over the world to become a global leading enterprise with large-scale intelligent manufacturing capabilities. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2025-08-28

中創新航（3931.HK）公佈2025年中期業績：上半年期內利潤大增80.4% 動力儲能雙驅動全球化佈局提速

香港，2025年8月28日 - (亞太商訊 via SeaPRwire.com) - 8月27日，中創新航科技集團股份有限公司（「中創新航」或「公司」，股票代碼：3931.HK），公佈截至2025年6月30日止六個月（「報告期」）的未經審計簡明合併中期業績。報告顯示，上半年公司經營表現亮眼，實現營業收入人民幣16,418.88百萬元，較上年同期顯著增長31.7%；期內利潤實現人民幣752.99百萬元，同比大幅增長80.4%，在全球可再生能源發展加速轉型的態勢中展現出強勁的盈利能力與發展韌性。根據權威機構SNE Research統計，中創新航2025年上半年全球動力電池裝車量同比增長22.7%，排名穩居國內第三、全球第四，單月裝車量已達4.7GWh。在國內乘用車市場，公司表現尤為突出，6月、7月市占率連續創下新高，分別達到7.4%和8.25%。儲能領域增速更為迅猛，InfoLink資料顯示，公司上半年儲能電芯出貨量躍升至全球前四，實現里程碑式發展。支撐這一系列成績的，是中創新航技術的持續突破和多款重磅產品的量產落地。上半年，中創新航攜「頂流」電池持續引領技術前沿，公司400Wh/kg固液混合電池產品即將量產配套，全固態電池研發取得突破、生產線貫通投用。此外，公司高功率磷酸鐵鋰R46大圓柱電池實現行業內首家量產配套，成功助力吉利、東風最新混動車型；而下一代210Wh/kg以上能量密度磷酸錳鐵鋰電池產品也即將批量應用，該產品可實現10%電量至80%電量充電時間15分鐘，產品性能進一步提升。在乘用車市場，憑藉卓越的產品實力，中創新航成功實現大眾、現代、豐田全球前三大車企集團全部進入。上半年，其800V 5C電池實現月銷量超2萬台，順利推進配套小鵬、樂道、零跑、奧迪、北汽等多個車型，該超充電池三元版本獨家配套全新小鵬P7，並助力其創下24小時行駛3971公里的全球紀錄。在商用車領域，中創新航構建至遠電池全場景、全覆蓋、全賦能的產品矩陣架構，上半年國內商用車裝車量同比增長310%。公司行業首推輕卡車型百萬公里定製版，大幅提升電池系統質保，獲得業內廣泛認可，目前已與奇瑞、吉利、瑞馳、福田、東風、長安、金龍等知名企業深度合作。在重商領域，公司以場景化電量設計深耕市場，與重汽、徐工、三一、陝汽、解放、東風、臨工、柳工等客戶在多方面達成全方位合作。伴隨著國際市場的重大突破，中創新航上半年儲能業務發展迅猛。其314Ah二代長迴圈儲能電芯憑藉96%以上的能效、15,000次的超長壽命、前1,000次迴圈零衰減的卓越性能獲得國內國際客戶的高度認可，並成功斬獲拉美和南非最大電站專案，進入多家頭部開發商和電網公司的供應商名錄。另外，公司新一代「至久」588Ah、600Ah+儲能大電芯亦將於今年量產。除此之外，作為行業首家通過eVTOL動力電池製造符合性審查的企業，中創新航大力探索新興市場，助力我國低空經濟發展。目前，公司310Wh/kg的R46圓柱電芯已量產配套行業頭部eVTOL企業。同時，中創新航已與廣汽高域簽署深化戰略合作協定，約定在eVTOL領域展開深入合作，共同推進eVTOL電源標準化產品的發展。整體來看，中創新航上半年圍繞「產品與技術領先」戰略，加速全球化產能佈局。目前，泰國Pack工廠已穩定交付，且葡萄牙基地也已於2025年一季度破土動工，未來隨著其產業鏈佈局的進一步完善，中創新航有望憑藉跨領域、跨場景的動儲產品矩陣，實現動儲業務深度協同，全場景打造硬核產品力，同時，持續開拓軌道交通、礦山礦用、低空飛行、人形機器人等新興市場，持續推進「能源+」戰略落地，進一步推進在全球新能源產業中的領先地位。關於中創新航集團有限公司中創新航（3931.HK）是專業從事鋰電池、電池管理系統及相關整合式產品和鋰電池材料的研製、生產、銷售和市場應用開發的新能源高科技企業。作為電池專家，公司致力於構建全方位能源運營體系，為以動力及儲能為代表的新能源全場景應用市場提供完善的產品解決方案和全生命週期管理。目前，公司已建立江蘇、福建、四川、湖北、安徽、廣東等多個產業基地，完成全方位國內產業佈局，同時已設立歐洲產業基地、泰國產業基地，大力拓展海外產業佈局，打造擁有規模化智慧製造實力的國際化領先企業。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2025-08-28